
==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067
MDPI

10.3390/ijms222212499
ijms-22-12499
Review
Non-Cell Autonomous and Epigenetic Mechanisms of Huntington’s Disease
Kim Chaebin 1†
Yousefian-Jazi Ali 1†
Choi Seung-Hye 1
Chang Inyoung 2
Lee Junghee 345*
https://orcid.org/0000-0001-6544-3732
Ryu Hoon 1*
Valor Luis M. Academic Editor
1 Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea; cbkim@kist.re.kr (C.K.); yousefian@kist.re.kr (A.Y.-J.); shchoi323@kist.re.kr (S.-H.C.)
2 Department of Biology, Boston University, Boston, MA 02215, USA; ic313@bu.edu
3 Boston University Alzheimer’s Disease Research Center, Boston University, Boston, MA 02118, USA
4 Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA
5 VA Boston Healthcare System, Boston, MA 02130, USA
* Correspondence: junghee@bu.edu; Tel.: +1-857-364-6034 (J.L.); hoonryu@kist.re.kr; Tel.: +82-2-958-6855 (H.R.)
† These authors equally contributed to this review.

19 11 2021
11 2021
22 22 1249905 10 2021
15 11 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Huntington’s disease (HD) is a rare neurodegenerative disorder caused by an expansion of CAG trinucleotide repeat located in the exon 1 of Huntingtin (HTT) gene in human chromosome 4. The HTT protein is ubiquitously expressed in the brain. Specifically, mutant HTT (mHTT) protein-mediated toxicity leads to a dramatic degeneration of the striatum among many regions of the brain. HD symptoms exhibit a major involuntary movement followed by cognitive and psychiatric dysfunctions. In this review, we address the conventional role of wild type HTT (wtHTT) and how mHTT protein disrupts the function of medium spiny neurons (MSNs). We also discuss how mHTT modulates epigenetic modifications and transcriptional pathways in MSNs. In addition, we define how non-cell autonomous pathways lead to damage and death of MSNs under HD pathological conditions. Lastly, we overview therapeutic approaches for HD. Together, understanding of precise neuropathological mechanisms of HD may improve therapeutic approaches to treat the onset and progression of HD.

Huntington’s disease
non-cell autonomous pathway
astrocyte
oligodendrocyte
epigenetics
mitochondria dysfunction
vesicle trafficking
therapeutic targets
==== Body
pmc1. Introduction

Huntington’s disease (HD) is a fatal progressive neurodegenerative disorder with a mid-life onset which ranges from infancy to the ninth decade. HD occurs in 5–10 cases per 100,000 persons worldwide, and characterized by chorea, emotional distress, and progressive cognitive decline [1]. Generally, in HD patients, there are more than 38 repeats of trinucleotide CAG within the Huntingtin (HTT) gene with an inverse relationship between the number of CAG repeats and the age of onset, indicating that the high number of CAG repeats cause the earlier phenotype of HD symptoms [2,3,4]. HTT has a crucial role in embryonic development by showing the death of embryos of huntingtin homozygous knockout mice by day 7.5 [5]. On the other hand, HTT plays an important role in cardiomyocytes cellular energy and nucleotides metabolism [6].

Currently, HD is considered as a multi-systemic neurodegenerative disease due to skeletal muscle and heart function disturbances with energy metabolism and mitochondrial alterations beyond the brain dysfunction [7]. Although most of studies show intracellular inclusions formed by mutant HTT (mHTT) protein in selected regions of the brain such as the striatum and cortex of HD brain [8,9], other studies find the expression and function of mHTT in skeletal muscle and heart as well [10]. The mHTT is involved in transcriptional alterations, disruption of intracellular transport, excitotoxicity, collapse of protein degradation mechanisms, mitochondrial dysfunction, and disorders of myelin, which make neurons more susceptible to generic stresses, eventually leading to neuronal death [11,12,13,14]. Yamanishi et al. have reported a novel cell death pathway known as transcriptional repression-induced atypical cell death of neurons (TRIAD) in the HD pathology, exhibiting that enlargement of endoplasmic reticulum (ER) contributes to neuronal cell damage without alteration of mitochondria and nuclei structure [15]. Another study has shown that inflammation may play a role in cardiac dysfunction in HD by overexpression of the inflammatory cytokine, tumor necrosis factor-α, in cardiomyocytes of R6/2 HD mice [16].

The epigenetic modifications are closely associated with the pathogenesis of HD [17,18]. mHTT sequesters specific transcription factors and impairs their function, resulting in disruption of their target genes transcription [19,20,21]. mHTT also regulates transcription by facilitating transcriptional factor interaction with protein complexes [22]. Otherwise, mHTT leads to histone hypoacetylation which can change genes expressions [23,24,25]. Moreover, several studies have shown that the biochemical defect and impairment of neuronal energy metabolism in HD patients are caused by mitochondrial dysfunction, where mitochondria is a major contributor of energy production and a regulator of intracellular signaling and survival [26,27]. The calcium-ion (Ca2+) buffering abnormalities and bioenergetic impairments in mitochondria can occur by interaction of mHTT with mitochondrial proteins [28,29,30]. Recently, researchers have become more interested in identifying the roles of non-neuronal cells in HD pathophysiology through elucidation of alterations in oligodendrocyte functions such as myelin formation [31,32,33] and astrocyte morphological changes and functions including impairment of glutamate metabolism and potassium homeostasis [34,35,36]. In this review, we discuss how astrocytes and oligodendrocytes contribute to HD pathogenesis via a non-cell autonomous pathway. Furthermore, we review the different epigenetic modifications which have key roles in neurotoxicity and neurogenesis impairment, and finally discuss potential therapeutic strategies for HD.

2. Non-Cell Autonomous Cell Death Pathway in HD

While the primary causes of neuronal damage and cell death are abnormalities within the damaged neuron itself, other neighboring cells such as glial cells also contribute to neuronal death [37,38]. In this regard, non-cell autonomous pathway is defined in this review as the mechanism of the neuronal damage caused by non-neuronal cells. Recent studies have proven the non-cell autonomous pathway in that reactive astrocytes lead to neuronal damage and neurodegeneration in Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), HD, and Parkinson’s disease (PD) [39,40,41,42]. Indeed, neuron-specific expression of mHTT in the striatum and cortex is not sufficient to fully induce pathological phenotypes of HD [43]. Otherwise, astrocyte-specific expression of mHTT does not induce neurodegeneration, but it shows neurological symptoms [44]. In the HD fly model (UAS HttQ100-mRFP) where mHTT is expressed in neurons, suppression of mHTT aggregation specifically in astrocytes expands the lifespan of HD fly [45]. On the other hand, white matter is degenerated and the oligodendrocyte differentiation is defective in HD [46]. mHTT-expressing microglia are hyperreactive to inflammatory stimuli to cause synaptic dysfunction in dendritic spines [47,48,49], where neurons try to control microglia activation but fail in HD [50]. Both mHTT and wtHTT are secreted from brain cells [51], where mHTT oligomers disrupt energy metabolism of neighboring cells [52]. mHTT not only affects brain metabolism, it also causes the dysfunction of other organs such as liver [53]. In the below sections, we discuss how mHTT affects astrocytes and oligodendrocytes in the neuropathogenesis of HD.

2.1. Alteration of Astrocyte Function

Astrocytes support neural functions by managing local environments including nutrients, ions, and neurotransmitters. In addition to the role as a generic supporter of neurons, astrocytes are involved in information processing [54], especially in the form of tripartite synapse [55]. Within the tripartite synapse, astrocytes tightly envelop synapses to clear residual neurotransmitters and ions after synaptic activities [56]. Failure in clearance of the residuals leads to accumulation of the neurotransmitters and ions. Excessive buildup of excitatory neurotransmitter such as glutamate is toxic to neurons and eventually causes neurodegenerative diseases [57]. High concentration of extracellular potassium ion depolarizes the membrane potential and contributes to the hyperexcitability of local neurons [58].

In the brain of HD patients, degeneration of medium spiny neurons (MSNs) in the striatum starts in the early stage of the disease before the widespread cell death in the striatum. The mechanism of the degeneration of MSNs is regulated by glutamate-mediated excitotoxicity via N-methyl-D-aspartate receptor (NMDAR) [40]. NMDAR is composed of three types of subunits (GluN1, GluN2A-D, and GluN3A-B), where NMDAR that contains GluN2A or GluN2B control synaptic dynamics [59]. Particularly, GluN2B-type NMDARs are phosphorylated by death-associated protein kinase to serve as toxic receptors [60]. Here, GluN2B-type NMDAR is highly expressed in mature MSNs of striatum, which is the reason behind the selective vulnerability of MSNs in HD [61,62]. Striatal neurons in HD show upregulated surface expression of GluN2B-type NMDAR due to the dysfunction of the huntingtin-interacting protein 14L [63]. Otherwise, gene silencing of a glutamate receptor subunit reverses HD phenotype [64]. Excitotoxicity is also studied systemically. Considering that most glutamatergic input of striatum is from the cortex, destruction of cortico-striatal pathway is a key process in presymptomatic phase of the disease [65]. Dysfunction of MSNs increases the excitation from the cortex in the form of positive feedback loop and exacerbates the excitotoxicity [66]. Interestingly, NMDAR response in the corticostriatal synapse is rescued to normal state by astrocyte-specific reduction of mHTT in BACHD mice [67]. In this context, astrocytes are recently reviewed as a player in excitotoxicity in HD and other neurodegenerative disorders [11,35,39,40,41,42,68,69,70,71,72,73,74,75,76,77].

In HD astrocytes, mRNA level of excitatory amino acid transporter 2 (EAAT2) is lower compared to that of the normal group [78,79]. In addition, protein level of EAAT2 is reduced throughout whole brain [34,80,81]. Low EAAT2 level is rendered as decreased glutamate uptake [82,83,84], which results in neuronal degeneration from chronic glutamate stimulation [85]. In addition, downregulation of an inwardly rectifying potassium channel, Kir4.1, in HD astrocytes results in increased extracellular K+ concentration, which subsequently increases the resting membrane potential of nearby neurons to make the neurons more excitable [86]. Interestingly, downregulation of EAAT2 and Kir4.1 in astrocytes not only induces hyperexcitability of neurons, but also induces evoked Ca2+ signaling in the astrocytes [87]. Increase of evoked Ca2+ level in astrocytes increases sodium pump activity which further increases extracellular K+ concentration [88] (Figure 1, Table 1).

2.2. Alteration of Oligodendrocyte Function

Oligodendrocytes are a type of glial cells in the brain and the spinal cord which produce myelin sheaths and play an important role in maintaining axonal integrity and function. Although oligodendrocytes are less explored in HD in previous studies, defective oligodendrocyte functions and deficient myelination are commonly observed in other neurodegenerative diseases [91]. Myers et al. are the first time to show an increase of oligodendrocytes in the striatum but no changes in astrocytes in postmortem HD brains [92]. Later, the other researchers identify myelin damage and breakdown in pre-symptomatic HD patients [93,94]. The full-length myelin regulatory factor (fMYRF) is self-cleaved to N-terminal myelin regulatory factor (nMYRF) which was transferred from the ER to the nucleus. In HD, binding of mHTT to nMYRF deficits normal bindings of nMYRF transcription factor in nucleus which leads to inhibition of myelination-related genes expression and oligodendrocyte dysfunction [95,96,97] (Figure 2). On the other hand, Cui et al. show that the expression of proliferator-activated receptor-gamma coactivator (PGC)-1α is significantly downregulated in HD striatal cells and tissues. In HD, mHTT interferes with promoter binding of cAMP response element binding protein (CREB) and TATA-binding protein-associated factor (TAF), which regulate the expression of PGC-1α. This mis-binding leads to the inhibition of PGC-1α expression which may cause reduction of myelin basic protein (MBP) expression and myelination deficit [98,99] (Figure 2). In parallel with these results, Xiang et al. also show the downregulation of MBP and deficient myelination in the oligodendrocytes of R6/2 transgenic mouse model of HD, and in the striatum of PGC-1α knockout mice as well [100]. Further study is necessary to verify whether PGC-1α rescues myelination in HD models in a cell-type-specific manner.

3. The Role of Epigenetic Modifications and Noncoding RNAs in the Pathogenesis of HD

Better understanding of epigenetic mechanisms may provide important insights, resulting in improved therapeutic approaches for treating HD [101]. In this section, we discuss the epigenetic changes and mechanisms that are associated with the pathogenesis of HD. We focus on two main epigenetic alterations that influence chromatin structure: DNA and histone modifications [102]. DNA methylation and hydroxymethylation have been involved in different neurodevelopmental and psychiatric disorders [103,104,105]. In DNA methylation, methyl groups are transferred to the cysteine 5 position of cytosine via the action of DNA methyltransferases [106]. Ng et al. propose that mHTT has a significant effect on changing the methylation of promoter regions of octamer-binding transcription factor 1 (OCT4), sex determining region Y-box 2 (SOX2), and Nanog homeobox (NANOG) as these genes are involved in neurogenesis. Therefore, inhibition of the expression level of these genes may lead to neurogenesis impairment and cognitive decline in HD [107] (Figure 3). In addition, histone modification is another major epigenetic mechanism which plays a special role in unraveling the pathogenesis of HD. CREB binding protein (CBP) interacts with several transcription factors such as specificity protein 1 (SP1), TAF, and RNA polymerase II, and acts as a co-activator or a repressor of transcription [108,109]. The CBP can also be considered as a histone acetyltransferase which acetylates histones to alter chromatin structure [110]. The mHTT interaction with CBP blocks its transcriptional co-activator function and inherent CBP histone acetyltransferase activity [111]. Therefore, CBP sequestration and depletion are accompanied by histone hypoacetylation, resulting in neuronal transcriptional dysfunction and neurotoxicity [112,113,114] (Figure 3).

Our group has found that SET domain bifurcated histone lysine methyltransferase 1 (SETDB1/ESET), a histone H3 at lysine 9 (H3K9)-specific methyltransferase, is elevated in the striatal neurons of HD patients and HD transgenic (R6/2) mice [115]. In parallel, the level of histone H3K9me3 is increased in the striatal neurons of HD patients and in HD transgenic (R6/2) mice. This study has proven that the SETDB1-H3K9me3 pathway is involved in silencing of genes in HD. Interestingly, not only SETDB1 modulates the nuclear gene transcription though heterochromatin remodeling, but it also down regulates the nucleolar gene transcription (ribosomal DNA components) by increasing methylation of upstream binding protein 1 (UBF1). SETDB1 interacts with UBF1 and trimethylates at lysine 232/235 in the nucleolus of striatal cells. As a result, trimethylated UBF1 leads to nucleolar chromatin condensation and down regulates the transcription of ribosomal DNA (rDNA) [12]. This study presents a novel epigenetic mechanism that SETDB1-UBF1 trimethylation pathway is associated the nucleolar chromatin remodeling and dysfunction of rDNA transcription in the pathogenesis of HD.

Moreover, several studies have focused on microRNAs (miRNAs) which are involved in the early differentiation, development, and function of neurons [116,117]. miR-146a is one of the major regulators of the NF-κB pathway which can also target human and mouse HTT gene [118,119]. Das et al. demonstrate that heat shock factor 1 is regulated by this miRNA, resulting suppression of mHTT aggregates in HD cells [120]. Another study confirmed that miR-214 directly targets the HTT gene which can suppress mHTT aggregation in an HD mouse striatal cell and HEK293T cell [120,121]. On the other hand, Bucha et al. showed the upregulation of miRNA-214 in HD cells could regulate mitofusin2, resulting in alteration of mitochondrial morphology [122]. Therefore, this miRNA can be considered as a critical node for therapeutic targets in HD pathogenesis.

4. Roles of Wild Type HTT (wtHTT) Versus mHTT in Vesicle Trafficking

Understanding the exact molecular and cellular functions of wtHTT and mHTT is crucial in further clarifying the pathogenesis of HD. wtHTT is involved in axonal transport, which is essential for neuronal synaptic activity [123]. Transport of cargo is important for neuron to work properly because of its unique morphology containing axons and dendrites. Vesicular transport is accelerated by overexpression of wtHTT [124]. There are emerging models to explain how wtHTT coordinates vesicular transport and ongoing studies to discover a more detailed mechanism of coordination and the HD pathology related to vesicle transport [125] (Figure 4).

wtHTT recruits glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to transport vesicles, where vesicular GAPDH produce adenosine 5′-triphosphate (ATP) to provide energy for the transport [126]. In HD pathogenesis, GAPDH is sequestered by mHTT [127,128], where the sequestration of GAPDH is rescued by high-affinity RNA aptamers that specifically recognize mHTT [129]. In addition, HTT forms complexes of motor proteins with huntingtin-associated protein-1 and p150Glued subunit of dynactin [130]. HTT-associated protein-1 binds to both kinesin-1 and vesicles to serve as an adaptor [131]. Huntingtin’s recruitment of kinesin-1 is governed by the phosphorylation of wtHTT at serine421 (Ser421), which stimulates anterograde transport [132]. Interestingly, phosphorylation of HTT (Ser421) protects against the mHTT toxicity, where the endogenous level of phosphorylated HTT (Ser421) is least in the striatum [133].

Defects in the axonal transport are associated with neurodegenerative diseases. For example, mutations in amyloid beta precursor protein obstruct motor protein activity of the hippocampal and cortical neurons in AD, and mutation in superoxide dismutase type-1 impede binding of motor proteins to neurofilaments of motor neurons in ALS [134]. In fact, fast axonal transport is commonly disrupted in polyglutamine-expansion diseases [135]. In HD, fast axonal transport is slowed down specifically in striatal neurons [136]. The impairment of the vesicular transport induces axonal degeneration, which is the early neuropathology of HD [137].

Pathogenic HTT disrupts the motility of vesicle complex, accessory proteins, and molecular motors [138], hence, the efficiency of vesicle trafficking [131,139] (Figure 4). Comparably, both HTT-depleted neurons and mHTT-expressing neurons suffer from defective axonal transport [140], where motor proteins are sequestered by mHTT [141]. Tubulin acetylation is also reduced in HD resulting in reduced binding of motor proteins to microtubules [142]. Vesicle trafficking related proteins such as HTT interacting protein 1, dynamin, and endophilin-A3 are depleted by mHTT bodies [143].

On the other hand, mHTT activates axonal c-Jun amino-terminal kinase3 via stress-signaling kinase [144], where inhibition of the c-Jun amino-terminal kinase/c-Jun partially restores striatal neurodegeneration in HD [85]. Consequently, kinesin-1 is phosphorylated at serine 176, which results in detachment of kinesin-1 and cargo from the microtubules [145].

Despite the growing evidence of mHTT and its effects on vesicle trafficking in neurons, further study is necessary to define why MSNs are much more susceptible to mHTT than other neuronal cell types. Additionally, precise cellular and molecular mechanism of mHTT oligomers versus mHTT aggregates-dependent vesicle trafficking should be determined.

In addition, wtHTT is also involved in autophagy as reviewed in [146]. wtHTT form complex with sequestosome 1 to enhance cargo recognition, where depletion of wtHTT results in empty autophagosome [147]. C-terminal domain of wtHTT has structural homology with yeast autophagy scaffold protein 11 and both proteins show similar protein–protein interaction patterns [148]. Interestingly, deletion of N-terminal domain of wtHTT in mouse suffers from DNA damage in striatum and cortex without any difference in autophagy function [149]. wtHTT is also associated with ER, where ER stress release the wtHTT to promote autophagy (reviewed in [150]). In addition, wtHTT has important role in homeostasis of presynaptic and postsynaptic terminal [151]. Loss of wtHTT lead to dysfunction of synaptic vesicle endocytosis in striatal neurons [152].

We need to provide attention to an important HD pathophysiology that the dysfunctions of central nervous system and other organs in HD are caused by mHTT accumulation as well as by the loss of functionality of wtHTT protein. Molecular simulation reveals that mHTT oligomer also sequester wtHTT [153]. Indeed, wtHTT protein expression level is inversely correlated to the age of onset [154]. In macrophage, reduced wtHTT level is associated with decreased cytokine and increased phagocytosis [155]. Research is ongoing to reveal the wtHTT function and structure further. RNA-seq of wtHTT knockout neural cell shows that wtHTT has a role in development of neurons and neurotransmission [156]. Cryo-electron microscopy structure of wtHTT confirms its role in protein–protein interaction [157]. The importance of the loss of functionality of wtHTT is associated with clinical safety of HTT gene therapy as reviewed previously [158].

5. Mitochondria Dysfunction in HD

A growing body of evidence show that mitochondrial dysfunctions, including membrane potential and respiratory function deficits, Ca2+ buffering capacity reduction, and mitochondrial number and morphology alteration, play a critical role in HD pathogenesis [159,160,161,162,163,164,165]. The mHTT aggregation reduces the mitochondrial membrane potential and increases the level of mitochondrial matrix Ca2+ loading that leads to decreased ATP level and enhanced reactive oxygen species (ROS) [160,166,167]. Moreover, the release of cytochrome c from dysfunctional mitochondria leads to activation of caspases 9 and 3 which are involved in apoptosis, resulting in neuronal cell death [168,169] (Figure 5). On the other hand, Yablonska et al. show mHTT binding with high affinity to translocase of mitochondrial inner membrane 23 (TIM23) complex in mitochondrial intermembrane space leads to inhibition of import of nuclear-encoded proteins through TIM23 [14]. Therefore, the mHTT–TIM23 complex interaction alters mitochondrial proteome, resulting in mitochondrial dysfunction in HD [170] (Figure 5). In addition, Guo et al. showed that valosin-containing protein (VCP) is bound to mHTT as a binding protein on the mitochondria. Mitochondria-accumulated VCP works as a mitophagy adaptor to bind to the autophagosome component, microtubule-associated proteins 1A/1B light chain 3B (LC3), leading to enhanced mitophagy, reduced mitochondrial mass, and ultimately, neuronal cell death [28,171] (Figure 5). Moreover, the previous studies demonstrated that down regulation of wtHTT is related to mitochondria dysfunction by inability of the mitochondria to generate ATP [172] and diminished purines and inosine monophosphate [6].

6. Therapeutic Approaches for Huntington’s Disease

Despite remarkable efforts to overcome the symptoms of HD, effective therapeutic targets are still very limited in HD. Furthermore, no standard treatment has been established for HD. HD transgenic mouse models have been used for translational study with many candidate drugs before conducting clinical trials with patients, but the efficacy of most drugs is lower than expected [173]. Accordingly, the benefits of translating the therapeutic efficacy from the HD transgenic mouse models to human patients are not clear.

Gene editing method and strategy have been attempted for treating various genetic disorders including HD. Clustered regularly interspaced short palindromic repeats and (CRIPSR) and CRISPR-associated genes (CRISPR/Cas9) has been applied haplotype-specifically to common promoter-local single-nucleotide polymorphisms (SNPs) for the selective deletion of mHTT [174,175,176,177]. Otherwise, Zinc finger proteins containing the Kruppel associated box (KRAB-ZFPs), short hairpin RNA (shRNA), small interfering RNA (siRNA), and miRNA have been examined to impair transcription of mHTT [178,179,180,181,182,183,184,185]. To use siRNA or antisense oligonucleotide to knock-down mRNA of mutant Hunting requires repetitive administration. shRNA treatment lasts relatively longer than siRNA treatment; however, the dosage control of shRNA treatment is limited [186]. miRNA therapy suffers from off-target effect in general, which is recently overcome using in silico analysis [187]. Glutamine repeat-binding [188] and deletion [189] on mHTT gene are also effective in HTT lowering and alleviate HD phenotypes. For further information, gene targeting approaches are reviewed in [190,191,192,193,194,195,196,197,198,199,200,201].

Among many small compounds, epigenetic modulators have been used for rescuing transcriptional dysfunction in HD. For example, phenylbutyrate, sodium butyrate, histone deacetylases inhibitor (HDACi) 4b and LBH589, Tubastatin A, and CKD-504 hinder histone deacetylase increase the acetylation of H3K9, and improve neuropathology, behaviors, and survival of HD transgenic mice [202,203,204,205,206,207,208]. Importantly, epigenetic compounds exhibit transgenerational effect in HD animal models [205]. Mithramycin, a DNA binding drug, inhibits expression of histone methyltransferase, reduces H3K9me3 level and heterochromatin condensation, and ameliorates symptoms of HD [209]. In order to improve the efficacy of epigenetic compounds, further efforts to reduce the side effect of these drugs need to be made.

In addition to HD genetic and epigenetic targets, pathologic phenotypes including HTT fragmentation and aggregates, transcriptional dysfunction, oxidative stress, apoptosis, autophagy dysfunction, and excitotoxicity appear to be reasonable drug targets [101] (Table 2). The most effective therapeutic strategy in HD is to target the inhibition of aggregation or fragmentation of mHTT, because mHTT is directly responsible for the pathogenesis of HD. Cystamine, Congo red, Chrysamine G, direct fast yellow, and trehalose are drugs that bind to polyglutamine or block oligomerization, and consequently inhibit the aggregation of mHTT. Congo red, an organic compound and diazo dye, binds to β–sheets of protein structure of mHTT and prevents polyglutamate oligomerization. Since Congo red cannot cross the blood–brain barrier, compounds with similar structure of Congo red are discovered as potential drugs. Chrysamine G and direct fast yellow are found to effectively inhibit mHTT aggregation [210]. Saccharides including trehalose also bind directly to the polyglutamate region of mHTT to suppress the mHTT aggregation effectively [211]. Both antibodies which binds polyproline domain of mHTT and DnaJ heat shock protein family member B6 also reduce mHTT aggregation [212]. Otherwise, insulin, exendin-4, GM1, RCAN1-IL, and SGK block mHTT aggregation by increasing mHTT phosphorylation and modifying mHTT toxicity through post-translational modification. Increasing the phosphorylation of mHTT enhances solubility and decreases aggregation. Surprisingly, phosphorylation of mHTT on Ser 421 is known to be neuroprotective [213,214]. Formation of mHTT aggregate is exacerbated by transglutaminase, which cross-links mHTT. Inhibition of transglutaminase with cystamine reduces abnormal behavior, extends lifespan, and prevents weight loss of HD transgenic (R6/2) mice. In addition, cystamine injected HD mice have higher expression level of Dnajb1, which catalyze ATP hydrolysis. In addition to the mHTT aggregation, fragmentation of mHTT has been a plausible therapeutic target for HD because the pathology of HD is exacerbated by mHTT fragments including polyglutamate region [215]. Minocycline and Z-VAD-FMK inhibit caspases to prevent the proteolysis of mHTT and improve neuropathology of HD transgenic mice [216].

Interestingly, Rieux et al. (2020) tested whether a parabiosis therapy, an in vivo blood transfusion via surgical linking of two bodies, can reduce mHTT propagation and pathology in HD transgenic mice (zQ175 mice) [217]. It is concluded that blood transfusion improves mitochondrial activity in peripheral organs and ameliorates neuropathology in MSNs of striatum. This study indicates that healthy blood can diminish the pathogenicity of circulating mHTT. If the concentration of mHTT exceeds a certain concentration in the body, it is likely to cause a disease onset of HD systemically. In this paradigm, reducing the concentration of mHTT by removing circulating mHTT with blood transfusion can be another treatment. However, application of the parabiosis therapy for HD may need further verification in regard to unexpected adaptive immune reactions in vivo.

Mitochondrial dysfunction is also one of the therapeutic targets in HD. Creatine is applied to restore mitochondrial dysfunction as it deactivates mitochondrial permeability transition [218]. Coenzyme Q10 promotes electron transport chain activity, which in turn improves mitochondrial respiration [218,219,220]. Both creatine and coenzyme Q10 have been used as beneficial compounds in HD and progressed up to Phase II clinical trials. Mitochondrial dysfunction induces oxidative stress, which can be managed by antioxidants (reviewed in [221]). PGC-1α is associated with transcriptional regulation of mitochondria-related genes and is also the target of HD therapy (reviewed in [222]). rhIGF-1 increases glucose uptake and regulates energy metabolism in striatal neurons, and its therapeutic effect has been tested in HD transgenic mouse models (R6/2 and YAC128) [223]. Autophagy is also involved in the clearing and recycling of mHTT in MSNs and its function is impaired in HD [224]. Niclosamide reduces mHTT by increasing autophagy activity [225]. It seems likely that niclosamide is therapeutically more effective in increasing lysosomal degradation of ubiquitinated molecules including ubiquitinated mHTT rather than activating proteasomal activity [226]. Apoptotic cell death of MSNs has been a therapeutic target in HD [227]. MAP4343, 17EE2, and isoquercitrin are known to control stress responses and reduce apoptosis of MSNs in HD [228]. Z-VAD-FMK, Z-DEVD-FMK, Z-LEHD-FMK, PG3d, and lithium chloride are well-known apoptosis inhibitors and used to treat HD animal models (C. elegans and Rat) [216,226,227,229,230]. Laquinimod increase the brain-derived neurotrophic factor level in striatum of R6/2 mouse model and has the neuroprotective effect [231].

Continuous stimulation by excitatory or inhibitory neurotransmitter can damage MSNs in HD. Notably, controlling glutamate-induced neurotoxicity is one of many therapeutic strategies for treating HD and other neurodegenerative disorders (reviewed in [232]). Silencing of a glutamate receptor subunit could reverse HD phenotype [64]. Activation of NMDA receptors and cation channels elevates intracellular Ca2+ flux, impairs mitochondria function, and triggers neuronal cell death pathways. Memantine acts as an inhibitor of NMDA receptor, draws attention in HD therapy, and its clinical trials are on-going at phase 2 and phase 4, respectively. Otherwise, necrostatin-1, an inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and necrosis, shows positive effects for delaying the onset and improving motor behaviors while the survival extension is not improved in HD transgenic (R6/2) mice [77,233,234].

7. Conclusions

Since the mutation of HTT gene at exon 1 with glutamine repeats was identified as the cause of HD in 1993 [2], many studies have shown that mHTT proteins directly cause the neuropathogenesis of HD. wtHTT plays an important role in vesicular transport, which is an essential cellular event in MSNs, whereas mHTT disrupts vesicle transport by sequestrating motor proteins. Understanding of exact mechanisms on the mHTT-induced selective neuronal damage in the neostriatum is pivotal to develop beneficial therapeutic targets or strategies to ameliorate the neurodegeneration in HD. In this context, further investigations about effective clearance or detoxification of mHTT remain to be performed.

The brain is a multicellular organ. Accordingly, it is possible that mHTT-induced cellular dysfunctions are varied and differentially modulated in specific brain regions and cell-type specific manner. In terms of autonomous versus non-cell autonomous neuronal damage, it is also critical to determine which brain cell-types (e.g., excitatory neurons, inhibitory neurons, astrocytes, and oligodendrocytes) are vulnerable to mHTT and contribute to the pathogenesis of HD [11,70]. Importantly, gliosis, production of new astrocytes, microglia, and oligodendrocytes, is a prominent pathology in HD as well as in other neurodegenerative disorders (reviewed in [74,77]). Therefore, it is necessary to define how mHTT affects the fate of neuron and glia, and whether therapeutic targets can selectively modulate and rescue cell-type specific functions in HD.

The scope of this review is to briefly introduce the previous and recent studies about mechanisms of HD pathologies and therapeutic strategies and that our review has limitation in the scope. Just in case, for the readers need further information, we recommend the previous reviews dealt with the specific aspects of striatal vulnerability [248], white matter phenotype [249], cerebellar dysfunction [250], progression of cell type-specific phenotype [251], microglial activation [252], synapse [253], intracellular transmission of mHTT [254], protein–protein interactions [255], biochemical alterations and HTT dynamics [256,257], posttranslational modifications [258], proteostasis [259], autophagy [260,261], redox homeostasis [262], metabolism [263,264], HTT mRNA [265,266], Ca2+ and dopamine signaling [61], inflammation [267], in vitro modelling of HD [268,269], striatal neurogenesis [270], stem cell treatment [271,272,273,274,275,276,277,278,279], electric stimulation therapy [280], network connectivity in presymptomatic HD brain [281], non-motor symptoms [282], gut microbiome [283], human immunodeficiency virus [284], diagnosis [285,286], clinical progression [287], treatment for the symptoms [288], physical therapy [289], psychological interventions [290,291], and management of agitation [292]. Collectively, the previous studies have potential to reveal spatiotemporal and cell-type specific mechanism of HD pathology. The future challenges in HD research are brought by the complexity of the pathology from biochemical level [293,294,295,296,297,298,299,300,301,302,303] to system level [304,305,306,307,308]. Accordingly, the ultimate mechanisms of HD pathology can be further scrutinized by state-of-the art research methods such as multi-omics approach combining transcriptome, proteome, and interactome [309], big data analysis with machine learning [310], and meta-analysis combining the publicly available data [311]. On the other hand, the potential HD therapeutics should specifically modulate the function of the striatal neurons while they prevent the adverse behavior of glial cells. High-throughput in silico and in vitro screening of chemical libraries [312,313,314,315,316] are expected to expedite the designing of beneficial compounds for HD.

Previous studies indicate that epigenetic cellular events have been emerged as potential therapeutic targets in HD [12,109]. The reversible characters of epigenetic modifications during the pathogenesis of HD are reasonable therapeutic targets. It is highly expected that we can prevent neuronal damage more efficiently by balancing the epigenetic disequilibrium in HD before the pathogenesis becomes irreversible and degenerative under HD stress condition. In this regard, future therapeutic strategies and agents to treat HD should consider appropriate epigenetic targets and cell-type specificity. On the other hand, identification of blood cell-derived epigenetic markers that can mimic the brain molecular pathology, will facilitate the advanced diagnosis and treatment of HD. Taken together, development of cell-type specific epigenetic therapeutic targets will pave a way to slow down the onset and progress of HD.

Acknowledgments

The authors would like to thank Go Woon Choi in the BSI of KIST for her kind administrative support.

Author Contributions

C.K., A.Y.-J., S.-H.C. and H.R. wrote and revised the manuscript; C.K, A.Y.-J. and H.R. drew the figures; I.C. and J.L. edited the manuscript; and J.L. and H.R. read, reviewed, and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the National Research Foundation (NRF) grants (NRF-2018M3C7A1056894, and 2020M3E5D9079742), the National Research Council of Science & Technology (NST) grant (No. CRC-15-04-KIST) from Korea Ministry of Science, ICT and Future Planning (MSIP), and grants (2E30951, 2E30954 and 2E30962) from Korea Institute of Science and Technology of South Korea. This study was also supported by NIH grants (R01AG054156 to H.R. and R01NS109537 to J.L.).

Conflicts of Interest

The authors have no conflict of interest to declare.

Figure 1 Dysfunction of cortico-striatal tripartite synapse in HD. mHTT aggregation deregulates transcription of EAAT2 and Kir4.1 in astrocytes. Deregulation of EAAT2 leads to low expression level of astrocyte glutamate transporter and impairment of the glutamate uptake by astrocytes in the tripartite synapse. As a result, excess glutamate in synapse induces hyper-excitability of the post-synaptic neuron (medial spiny neuron in cortico-striatal synapse). Deregulation of Kir4.1 leads to impaired potassium buffering of astrocytes. As a result, elevated potassium ion concentration increases the membrane potential of neurons, where high membrane potential induces hyper-excitability. Prolonged hyper-excitability is rendered as cellular toxicity.

Figure 2 Oligodendrocyte dysfunction in HD. In the first pathway, full-length MYRF is self-cleaved to nMYRF which detaches from ER and is translocated to the nucleus to regulate the expression of myelin related genes. In HD, N-terminal mHTT binds nMYRF causing abnormal binding of nMYRF and deficit myelin genes expression. Second pathway shows inhibition of PGC-1α expression by interference of mHTT in co-binding of CREB and TAF4, leading to reduced activity in the cholesterol biosynthesis pathway and myelination deficit. Created with BioRender.com.

Figure 3 Epigenetic modifications associated with HD. The promoter regions of neurogenesis-related genes, OCT4, SOX2, and NANOG, are methylated in cells expressing mHTT which can lead to impaired neurogenesis. On the other hand, mHTT sequestrates CBP in nuclear inclusions which causes the hypermethylation and hypoacetylation of histone proteins and CBP depletion. Depletion of CBP from the nucleus of cells leads to histone hypoacetylation, nuclear and nucleolar transcriptional dysfunction and increase in neurotoxicity. Created with BioRender.com.

Figure 4 Role of HTT in normal vesicular transport and role of mHTT in disturbed vesicular transport in HD. In normal conditions, HTT participates in motor protein complex with dynactin, dynein, and kinesin. In addition, HTT recruits GAPDH to vesicles to supply energy, ATP to motor proteins. In HD, polyglutamine expansions of the mHTT sequester GAPDH and motor proteins. Microtubules are acetylated by mHTT to hinder binding of motor proteins on the microtubules.

Figure 5 Mitochondria dysfunction associated with HD. mHTT aggregation disrupts the mitochondrial membrane potential and increases excitotoxin-induced Ca2+ influx which leads to decreased ATP generation and increased ROS. Mitochondria dysfunction results in release of cytochrome C from the mitochondria which triggers the activation of apoptotic cascade via caspases 9 and 3, and neuronal injury. On the other hand, in HD, mHTT binds with high-affinity to TIM23 in mitochondrial intermembrane space, causing diminished levels of nuclear-encoded proteins imported through TIM23 and subsequently, neuronal death. Finally, VCP is selectively translocated to the mitochondria, where it is bound to mHTT and LC3 to enhance mitophagosome production, and reduce mitochondrial mass and energy supply, causing neuronal cell death. Created with BioRender.com.

ijms-22-12499-t001_Table 1 Table 1 Non-cell autonomous cell death pathway in HD related to astrocytes.

HD Pathology	Specimen	Brain Region/Cell Type	Experimental Method	Reference	
Less EAAT2 mRNA	Postmortem	Cingulate cortex	RNA sequencing	[78]	
Neostriatum	In situ hybridization	[79]	
Less EAAT2 protein	Postmortem	Striatum	Immunohistochemistry	[34]	
Striatum, cortex	Western blot	[80]	
Mouse; R6/2	Striatum, cortex, hippocampus, midbrain	Quantitative proteomics	[81]	
Less glutamate uptake	Postmortem	Prefrontal cortex	Glutamate uptake assay	[84]	
Cell; astrocyte	differentiated from Q77 monkey iPSC	Glutamate uptake assay	[82]	
Mouse; Q175	Single corticostriatal synapse	Imaging assay with glutamate sensor	[83]	
Less Kir4.1 mRNA	Postmortem	cingulate cortex	RNA sequencing	[78]	
Less Kir4.1 protein
Higher extracellular K+More excitable	Mouse; R6/2	Striatal MSN and astrocyte	qPCR, IHC, Western blot, Virus microinjection, Electrophysiology	[86]	
Altered Ca2+ signal	Mouse; R6/2	Striatal astrocyte	Virus microinjectionElectrophysiology	[87]	
More excitotoxicity	Cell; neuron and astrocyte	Co-culture of HD neurons and astrocytes from human iPSC	Cell count after glutamate exposure	[89]	
Co-culture of wild type neurons with mHTT infected glia from rat primary culture	[90]	

ijms-22-12499-t002_Table 2 Table 2 Therapeutic targets for HD.

Target	Strategy	Mode of Action	Disease Model	Clinical Trial & NCTno.	References	
mHTT gene	CRISPR/Cas9	Excise mHTT DNA selectively	Cell iPS		[174]	
Mouse BacHD		[175]	
Mouse HD140Q		[176]	
Mouse R6/2		[177]	
KRAB-ZFPs	Inhibition of translation or transcriptdegradation	Mouse R6/1,2		[178,179]	
shRNA	Mouse R6/2		[180]	
Mouse N171-82Q		[181,182]	
siRNA	Mouse HTT injected		[183]	
Mouse Hdh-150Q		[184]	
miRNA	Mouse HD140Q	Phase I/II [235], NCT04120493	[185]	
Antisense
nucleotide	Bind to HTT mRNA	Mouse BACHD	Phase II,
NCT02519036	[236,237]	
Transcriptional dysregulation	Phenylbutyrate	Inactivate histone deacetylase	Mouse N171-82Q	Phase II,
NCT00212316	[202]	
Sodium butyrate	Mouse R6/2		[203]	
HDACi 4b	Mouse N171–82Q		[204,205,206]	
HDACi LBH589	Transgenic Rodent HD Models		[207]	
Tubastatin A	Cell primary neuron		[208]	
CKD-504		Phase I, NCT03713892		
Mithramycin	Increase H3K9	Mouse R6/2		[209]	
mHTT aggregation	Cystamine	Suppress mHTT crosslinking	Mouse R6/2		[238,239]	
Congo red	Bind and inhibit polyglutamineoligomerization	Mouse R6/2		[240]	
ChrysamineG, Direct fast yellow		[210]	
Trehalose		[211]	
mHTT
fragmentation	Minocycline	Inhibit caspase	Mouse R6/2	Phase III, NCT00277355	[241]	
Z-VAD-FMK	Cell X57		[216]	
mHTT lowering	Blood transfusion	Remove circulating mHTT	Mouse zQ175		[217]	
mHTT
post-modification	Insulin,
exendin-4	Increase mHTT Phosphorylation	Cell SH-SY5Y		[242]	
GM1	Mouse YAC128		[243]	
RCAN1-1L	Cell ST14A		[244]	
SGK	Cell primary neuron		[245]	
Transactivation	KD3010	Increased PPARδ transactivation	Mouse pCAGGS-loxP-STOP-loxP		[246]	
Mitochondrial dysfunction	Creatine	Inactivate mitochondrial permeability transition	Mouse R6/2	Phase II, NCT00026988	[218]	
Coenzyme Q10	Enhance electron transport		Phase II, NCT00920699	[219,220]	
PGC-1α	Upregulate mitochondrial gene			[222]	
Metabolism	rhIGF-1	increase glucose uptake	Mouse YAC128
Mouse R6/2		[223]	
Autophagy	Niclosamide	Inhibit mTOR	Cell HEK293, N2a		[225]	
	MAP4343,
17βE2,
Isoquercitrin	Regulate stress response	C.elegans HD mutants		[228]	
Apoptosis	Z-VAD-FMK,
Z-DEVD-FMK,
Z-LEHD-FMK	Inhibit caspase	Cell primary neuron		[227]	
PG3d	Cell COS-7		[229]	
	Lithium chloride	Rat QA injected		[230]	
Excitotoxicity	Memantine	Inhibit NMDA receptor		Phase IV, NCT00652457; Phase II, NCT00652457		
Necrostatin-1	Inhibit RIP1
kinase	Mouse R6/2		[233,247]	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Exuzides A. Crowell V. Reddy S.R. Chang E. Yohrling G. Epidemiology of Huntington’s disease (HD) in the US medicare population Neurology 2020 94 670 32156693
2. The Huntington’s disease collaborative research group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes Cell 1993 72 971 983 10.1016/0092-8674(93)90585-E 8458085
3. Di Prospero N.A. Fischbeck K.H. Therapeutics development for triplet repeat expansion diseases Nat. Rev. Genet. 2005 6 756 766 10.1038/nrg1690 16205715
4. Ross C.A. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington’s disease and related disorders Neuron 2002 35 819 822 10.1016/S0896-6273(02)00872-3 12372277
5. Cattaneo E. Rigamonti D. Goffredo D. Zuccato C. Squitieri F. Sipione S. Loss of normal huntingtin function: New developments in Huntington’s disease research Trends Neurosci. 2001 24 182 188 10.1016/S0166-2236(00)01721-5 11182459
6. Tomczyk M. Glaser T. Ulrich H. Slominska E.M. Smolenski R.T. Huntingtin protein maintains balanced energetics in mouse cardiomyocytes Nucleosides Nucleotides Nucleic Acids 2020 accepted 10.1080/15257770.2020.1815769
7. Rüb U. Seidel K. Heinsen H. Vonsattel J.P. den Dunnen W.F. Korf H.W. Huntington’s disease (HD): The neuropathology of a multisystem neurodegenerative disorder of the human brain Brain Pathol. 2016 26 726 740 10.1111/bpa.12426 27529157
8. DiFiglia M. Sapp E. Chase K.O. Davies S.W. Bates G.P. Vonsattel J.P. Aronin N. Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 1997 277 1990 1993 10.1126/science.277.5334.1990 9302293
9. Ross C.A. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 1997 19 1147 1150 10.1016/S0896-6273(00)80405-5 9427237
10. Kojer K. Hering T. Bazenet C. Weiss A. Herrmann F. Taanman J.-W. Orth M. Huntingtin aggregates and mitochondrial pathology in skeletal muscle but not heart of late-stage R6/2 mice J. Huntingt. Dis. 2019 8 145 159 10.3233/JHD-180324 30814364
11. Creus-Muncunill J. Ehrlich M.E. Cell-autonomous and non-cell-autonomous pathogenic mechanisms in Huntington’s disease: Insights from in vitro and in vivo models Neurotherapeutics 2019 16 957 978 10.1007/s13311-019-00782-9 31529216
12. Lee J. Hwang Y.J. Kim K.Y. Kowall N.W. Ryu H. Epigenetic mechanisms of neurodegeneration in Huntington’s disease Neurotherapeutics 2013 10 664 676 10.1007/s13311-013-0206-5 24006238
13. Trushina E. Dyer R.B. Badger J.D. Ure D. Eide L. Tran D.D. Vrieze B.T. Legendre-Guillemin V. McPherson P.S. Mandavilli B.S. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro Mol. Cell. Biol. 2004 24 8195 8209 10.1128/MCB.24.18.8195-8209.2004 15340079
14. Yablonska S. Ganesan V. Ferrando L.M. Kim J. Pyzel A. Baranova O.V. Khattar N.K. Larkin T.M. Baranov S.V. Chen N. Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23 Proc. Natl. Acad. Sci. USA 2019 116 16593 16602 10.1073/pnas.1904101116 31346086
15. Yamanishi E. Hasegawa K. Fujita K. Ichinose S. Yagishita S. Murata M. Tagawa K. Akashi T. Eishi Y. Okazawa H. A novel form of necrosis, TRIAD, occurs in human Huntington’s disease Acta Neuropathol. Commun. 2017 5 19 10.1186/s40478-017-0420-1 28274274
16. Lin C.-L. Wang S.-E. Hsu C.-H. Sheu S.-J. Wu C.-H. Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington’s disease via suppressing oxidative stress, inflammation, and apoptosis Clin. Interv. Aging 2015 10 1173 1187 26229452
17. Bassi S. Tripathi T. Monziani A. Di Leva F. Biagioli M. Epigenetics of Huntington’s disease Adv. Exp. Med. Biol. 2017 978 277 299 28523552
18. Valor L.M. Understanding histone deacetylation in Huntington’s disease Oncotarget 2017 8 5660 5661 10.18632/oncotarget.13924 28086204
19. Li S.H. Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington’s disease Trends Genet. 2004 20 146 154 10.1016/j.tig.2004.01.008 15036808
20. Riley B.E. Orr H.T. Polyglutamine neurodegenerative diseases and regulation of transcription: Assembling the puzzle Genes Dev. 2006 20 2183 2192 10.1101/gad.1436506 16912271
21. Yamanaka T. Miyazaki H. Oyama F. Kurosawa M. Washizu C. Doi H. Nukina N. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor Embo. J. 2008 27 827 839 10.1038/emboj.2008.23 18288205
22. Zimmer-Bensch G. Epigenomic remodeling in Huntington’s disease—master or servant? Epigenomes 2020 4 15 10.3390/epigenomes4030015
23. Gray S.G. Targeting Huntington’s disease through histone deacetylases Clin. Epigenetics 2011 2 257 277 10.1007/s13148-011-0025-7 22704341
24. Sadri-Vakili G. Cha J.H. Mechanisms of disease: Histone modifications in Huntington’s disease Nat. Clin. Pr. Neurol. 2006 2 330 338 10.1038/ncpneuro0199
25. Vashishtha M. Ng C.W. Yildirim F. Gipson T.A. Kratter I.H. Bodai L. Song W. Lau A. Labadorf A. Vogel-Ciernia A. Targeting H3K4 trimethylation in Huntington disease Proc. Natl. Acad. Sci. USA 2013 110 E3027 E3036 10.1073/pnas.1311323110 23872847
26. Jenkins B.G. Koroshetz W.J. Beal M.F. Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy Neurology 1993 43 2689 2695 10.1212/WNL.43.12.2689 8255479
27. McBride H.M. Neuspiel M. Wasiak S. Mitochondria: More than just a powerhouse Curr. Biol. 2006 16 R551 R560 10.1016/j.cub.2006.06.054 16860735
28. Guo X. Sun X. Hu D. Wang Y.J. Fujioka H. Vyas R. Chakrapani S. Joshi A.U. Luo Y. Mochly-Rosen D. VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington’s disease Nat. Commun. 2016 7 12646 10.1038/ncomms12646 27561680
29. Oliveira J.M. Mitochondrial bioenergetics and dynamics in Huntington’s disease: Tripartite synapses and selective striatal degeneration J. Bioenerg. Biomembr. 2010 42 227 234 10.1007/s10863-010-9287-6 20454921
30. Yano H. Baranov S.V. Baranova O.V. Kim J. Pan Y. Yablonska S. Carlisle D.L. Ferrante R.J. Kim A.H. Friedlander R.M. Inhibition of mitochondrial protein import by mutant huntingtin Nat. Neurosci. 2014 17 822 831 10.1038/nn.3721 24836077
31. Faria A.V. Ratnanather J.T. Tward D.J. Lee D.S. van den Noort F. Wu D. Brown T. Johnson H. Paulsen J.S. Ross C.A. Linking white matter and deep gray matter alterations in premanifest Huntington disease Neuroimage Clin. 2016 11 450 460 10.1016/j.nicl.2016.02.014 27104139
32. Jin J. Peng Q. Hou Z. Jiang M. Wang X. Langseth A.J. Tao M. Barker P.B. Mori S. Bergles D.E. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington’s disease Hum. Mol. Genet. 2015 24 2508 2527 10.1093/hmg/ddv016 25609071
33. Teo R.T. Hong X. Yu-Taeger L. Huang Y. Tan L.J. Xie Y. To X.V. Guo L. Rajendran R. Novati A. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease Hum. Mol. Genet. 2016 25 2621 2632 10.1093/hmg/ddw122 27126634
34. Faideau M. Kim J. Cormier K. Gilmore R. Welch M. Auregan G. Dufour N. Guillermier M. Brouillet E. Hantraye P. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington’s disease subjects Hum. Mol. Genet. 2010 19 3053 3067 10.1093/hmg/ddq212 20494921
35. Khakh B.S. Beaumont V. Cachope R. Munoz-Sanjuan I. Goldman S.A. Grantyn R. Unravelling and exploiting astrocyte dysfunction in Huntington’s disease Trends Neurosci. 2017 40 422 437 10.1016/j.tins.2017.05.002 28578789
36. Meunier C. Merienne N. Jollé C. Déglon N. Pellerin L. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington’s disease Glia 2016 64 1841 1856 10.1002/glia.23022 27442486
37. Ilieva H. Polymenidou M. Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond J. Cell Biol. 2009 187 761 772 10.1083/jcb.200908164 19951898
38. Möller T. Neuroinflammation in Huntington’s disease J. Neural. Transm. 2010 117 1001 1008 10.1007/s00702-010-0430-7 20535620
39. Chun H. Im H. Kang Y.J. Kim Y. Shin J.H. Won W. Lim J. Ju Y. Park Y.M. Kim S. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2− production Nat. Neurosci. 2020 23 1555 1566 10.1038/s41593-020-00735-y 33199896
40. Heng M.Y. Detloff P.J. Wang P.L. Tsien J.Z. Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease J. Neurosci. 2009 29 3200 3205 10.1523/JNEUROSCI.5599-08.2009 19279257
41. Heo J.Y. Nam M.-H. Yoon H.H. Kim J. Hwang Y.J. Won W. Woo D.H. Lee J.A. Park H.-J. Jo S. Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson’s disease Curr. Biol. 2020 30 276 291.e9 10.1016/j.cub.2019.11.079 31928877
42. Lee J. Hyeon S.J. Im H. Ryu H. Kim Y. Ryu H. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS Exp. Neurobiol. 2016 25 233 240 10.5607/en.2016.25.5.233 27790057
43. Gu X. André V.M. Cepeda C. Li S.-H. Li X.-J. Levine M.S. Yang X.W. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington’s disease Mol. Neurodegener. 2007 2 8 10.1186/1750-1326-2-8 17470275
44. Jing L. Cheng S. Pan Y. Liu Q. Yang W. Li S. Li X.-J. Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice Mol. Neurobiol. 2021 58 5112 5126 10.1007/s12035-021-02451-5 34250577
45. Bason M. Meister-Broekema M. Alberts N. Dijkers P. Bergink S. Sibon O.C.M. Kampinga H.H. Astrocytic expression of the chaperone DNAJB6 results in non-cell autonomous protection in Huntington’s disease Neurobiol. Dis. 2019 124 108 117 10.1016/j.nbd.2018.10.017 30408590
46. Benraiss A. Mariani J.N. Tate A. Solly R. Capellano L. de Mesy Bentley K.L. Chandler-Militello D. Goldman S. Huntington Disease Mice Exhibit a TCF7L2-Responsive Suppression of Both Homeostatic and Compensatory Remyelination SSRN Electron. J. 2021 under review 10.2139/ssrn.3921284
47. Savage J.C. St-Pierre M.-K. Carrier M. El Hajj H. Novak S.W. Sanchez M.G. Cicchetti F. Tremblay M.-È. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington’s disease pathology J. Neuroinflammation 2020 17 98 10.1186/s12974-020-01782-9 32241286
48. Kim A. García-García E. Straccia M. Comella-Bolla A. Miguez A. Masana M. Alberch J. Canals J.M. Rodríguez M.J. Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington’s Disease Front. Cell. Neurosci. 2020 14 163 10.3389/fncel.2020.00163 32625064
49. O’Regan G.C. Farag S.H. Casey C.S. Wood-Kaczmar A. Pocock J.M. Tabrizi S.J. Andre R. Human Huntington’s disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species J. Neuroinflammation 2021 18 94 10.1186/s12974-021-02147-6 33874957
50. Bolla A.C. Valente T. Miguez A. Brito V. Gines S. Solà C. Straccia M. Canals J.M. CD200 is up-regulated in R6/1 transgenic mouse model of Huntington’s disease PLoS ONE 2019 14 e0224901 31790427
51. Caron N.S. Banos R. Yanick C. Aly A.E. Byrne L.M. Smith E.D. Xie Y. Smith S.E. Potluri N. Black H.F. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease J. Neurosci. 2021 41 780 796 10.1523/JNEUROSCI.1865-20.2020 33310753
52. Sameni S. Zhang R. Digman M.A. The phasor FLIM method reveals a link between a change in energy metabolism and mHtt protein spread in healthy Mammalian cells when co-cultured with Huntington diseased cells Methods Appl. Fluoresc. 2021 9 015005 10.1088/2050-6120/ab854d
53. Singh A. Agrawal N. Deciphering the key mechanisms leading to alteration of lipid metabolism in Drosophila model of Huntington’s disease Biochim. Et. Biophys. Acta (BBA)-Mol. Basis Dis. 2021 1867 166127 10.1016/j.bbadis.2021.166127 33722743
54. Sancho L. Contreras M. Allen N.J. Glia as sculptors of synaptic plasticity Neurosci. Res. 2020 167 17 29 10.1016/j.neures.2020.11.005 33316304
55. Perea G. Navarrete M. Araque A. Tripartite synapses: Astrocytes process and control synaptic information Trends Neurosci. 2009 32 421 431 10.1016/j.tins.2009.05.001 19615761
56. Halassa M.M. Fellin T. Haydon P.G. The tripartite synapse: Roles for gliotransmission in health and disease Trends Mol. Med. 2007 13 54 63 10.1016/j.molmed.2006.12.005 17207662
57. Brymer K.J. Barnes J.R. Parsons M.P. Entering a new era of quantifying glutamate clearance in health and disease J. Neurosci. Res. 2021 99 1598 1617 10.1002/jnr.24810 33618436
58. Florence G. Pereira T. Kurths J. Extracellular potassium dynamics in the hyperexcitable state of the neuronal ictal activity Commun. Nonlinear Sci. Numer. Simul. 2012 17 4700 4706 10.1016/j.cnsns.2011.06.023
59. Radiske A. Gonzalez M.C. Nôga D.A. Rossato J.I. Bevilaqua L.R.M. Cammarota M. GluN2B and GluN2A-containing NMDAR are differentially involved in extinction memory destabilization and restabilization during reconsolidation Sci. Rep. 2021 11 186 10.1038/s41598-020-80674-7 33420399
60. Schmidt M.E. Caron N.S. Aly A.E. Lemarié F.L. Dal Cengio L. Ko Y. Lazic N. Anderson L. Nguyen B. Raymond L.A. DAPK1 promotes extrasynaptic GluN2B phosphorylation and striatal spine instability in the YAC128 mouse model of Huntington disease Front. Cell. Neurosci. 2020 14 348 10.3389/fncel.2020.590569 33250715
61. Miller B.R. Bezprozvanny I. Corticostriatal circuit dysfunction in Huntington’s disease: Intersection of glutamate, dopamine and calcium Future Neurol. 2010 5 735 756 10.2217/fnl.10.41 21977007
62. Raymond L.A. André V.M. Cepeda C. Gladding C.M. Milnerwood A.J. Levine M.S. Pathophysiology of Huntington’s disease: Time-dependent alterations in synaptic and receptor function Neuroscience 2011 198 252 273 10.1016/j.neuroscience.2011.08.052 21907762
63. Kang R. Wang L. Sanders S.S. Zuo K. Hayden M.R. Raymond L.A. Altered regulation of striatal neuronal N-methyl-D-aspartate receptor trafficking by palmitoylation in Huntington disease mouse model Front. Synaptic Neurosci. 2019 11 3 10.3389/fnsyn.2019.00003 30846936
64. Marco S. Murillo A. Pérez-Otaño I. RNAi-based GluN3A silencing prevents and reverses disease phenotypes induced by mutant huntingtin Mol. Ther. 2018 26 1965 1972 10.1016/j.ymthe.2018.05.013 29914757
65. Cepeda C. Wu N. André V.M. Cummings D.M. Levine M.S. The corticostriatal pathway in Huntington’s disease Prog. Neurobiol. 2007 81 253 271 10.1016/j.pneurobio.2006.11.001 17169479
66. Bunner K.D. Rebec G.V. Corticostriatal dysfunction in Huntington’s disease: The basics Front. Hum. Neurosci. 2016 10 317 10.3389/fnhum.2016.00317 27445757
67. Wood T.E. Barry J. Yang Z. Cepeda C. Levine M.S. Gray M. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington’s disease mouse model Hum. Mol. Genet. 2019 28 487 500 10.1093/hmg/ddy363 30312396
68. Blumenstock S. Dudanova I. Cortical and striatal circuits in Huntington’s disease Front. Neurosci. 2020 14 82 10.3389/fnins.2020.00082 32116525
69. Chan C.S. Surmeier D.J. Astrocytes go awry in Huntington’s disease Nat. Neurosci. 2014 17 641 642 10.1038/nn.3705 24883452
70. Ehrlich M.E. Huntington’s disease and the striatal medium spiny neuron: Cell-autonomous and non-cell-autonomous mechanisms of disease Neurotherapeutics 2012 9 270 284 10.1007/s13311-012-0112-2 22441874
71. Estrada-Sánchez A.M. Rebec G.V. Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington’s disease: Interactions between neurons and astrocytes Basal. Ganglia 2012 2 57 66 10.1016/j.baga.2012.04.029 22905336
72. Gray M. The role of astrocytes in Huntington’s disease Pathological Potential of Neuroglia Springer Berlin/Heidelberg, Germany 2014 213 229
73. Gray M. Astrocytes in Huntington’s disease Neurogl. Neurodegener. Dis. 2019 1175 355 381
74. Palpagama T.H. Waldvogel H.J. Faull R.L. Kwakowsky A. The role of microglia and astrocytes in Huntington’s disease Front. Mol. Neurosci. 2019 12 258 10.3389/fnmol.2019.00258 31708741
75. Proft J. Weiss N. Rectifying rectifier channels in Huntington disease Commun. Integr. Biol. 2014 7 694 703 10.4161/cib.29410
76. Sánchez A.M.E. Mejía-Toiber J. Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington’s disease Arch. Med. Res. 2008 39 265 276 10.1016/j.arcmed.2007.11.011 18279698
77. Wilton D.K. Stevens B. The contribution of glial cells to Huntington’s disease pathogenesis Neurobiol. Dis. 2020 143 104963 10.1016/j.nbd.2020.104963 32593752
78. Al-Dalahmah O. Sosunov A.A. Shaik A. Ofori K. Liu Y. Vonsattel J.P. Adorjan I. Menon V. Goldman J.E. Single-nucleus RNA-seq identifies Huntington disease astrocyte states Acta Neuropathol. Commun. 2020 8 19 10.1186/s40478-020-0880-6 32070434
79. Arzberger T. Krampfl K. Leimgruber S. Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington’s disease—an in situ hybridization study J. Neuropathol. Exp. Neurol. 1997 56 440 454 10.1097/00005072-199704000-00013 9100675
80. Petr G.T. Schultheis L.A. Hussey K.C. Sun Y. Dubinsky J.M. Aoki C. Rosenberg P.A. Decreased expression of GLT-1 in the R6/2 model of Huntington’s disease does not worsen disease progression Eur. J. Neurosci. 2013 38 2477 2490 10.1111/ejn.12202 23586612
81. Skotte N.H. Andersen J.V. Santos A. Aldana B.I. Willert C.W. Nørremølle A. Waagepetersen H.S. Nielsen M.L. Integrative characterization of the R6/2 mouse model of Huntington’s disease reveals dysfunctional astrocyte metabolism Cell Rep. 2018 23 2211 2224 10.1016/j.celrep.2018.04.052 29768217
82. Cho I.K. Yang B. Forest C. Qian L. Chan A.W. Amelioration of Huntington’s disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington’s disease monkeys PLoS ONE 2019 14 e0214156 30897183
83. Dvorzhak A. Helassa N. Török K. Schmitz D. Grantyn R. Single synapse indicators of impaired glutamate clearance derived from fast iGluu imaging of cortical afferents in the striatum of normal and Huntington (Q175) mice J. Neurosci. 2019 39 3970 3982 10.1523/JNEUROSCI.2865-18.2019 30819797
84. Hassel B. Tessler S. Faull R.L. Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington’s disease Neurochem. Res. 2008 33 232 237 10.1007/s11064-007-9463-1 17726644
85. Garcia M. Charvin D. Caboche J. Expanded huntingtin activates the C-Jun N terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture Neuroscience 2004 127 859 870 10.1016/j.neuroscience.2004.05.054 15312898
86. Tong X. Ao Y. Faas G.C. Nwaobi S.E. Xu J. Haustein M.D. Anderson M.A. Mody I. Olsen M.L. Sofroniew M.V. Astrocyte Kir4. 1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice Nat. Neurosci. 2014 17 694 703 10.1038/nn.3691 24686787
87. Jiang R. Diaz-Castro B. Looger L.L. Khakh B.S. Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington’s disease model mice J. Neurosci. 2016 36 3453 3470 10.1523/JNEUROSCI.3693-15.2016 27013675
88. Bazargani N. Attwell D. Astrocyte calcium signaling: The third wave Nat. Neurosci. 2016 19 182 189 10.1038/nn.4201 26814587
89. Garcia V.J. Rushton D.J. Tom C.M. Allen N.D. Kemp P.J. Svendsen C.N. Mattis V.B. Huntington’s disease patient-derived astrocytes display electrophysiological impairments and reduced neuronal support Front. Neurosci. 2019 13 669 10.3389/fnins.2019.00669 31316341
90. Shin J.-Y. Fang Z.-H. Yu Z.-X. Wang C.-E. Li S.-H. Li X.-J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity J. Cell Biol. 2005 171 1001 1012 10.1083/jcb.200508072 16365166
91. Bankston A.N. Mandler M.D. Feng Y. Oligodendroglia and neurotrophic factors in neurodegeneration Neurosci. Bull. 2013 29 216 228 10.1007/s12264-013-1321-3 23558590
92. Myers R.H. Vonsattel J.P. Paskevich P.A. Kiely D.K. Stevens T.J. Cupples L.A. Richardson E.P. Jr. Bird E.D. Decreased neuronal and increased oligodendroglial densities in Huntington’s disease caudate nucleus J. Neuropathol. Exp. Neurol. 1991 50 729 742 10.1097/00005072-199111000-00005 1836225
93. Bartzokis G. Lu P.H. Tishler T.A. Fong S.M. Oluwadara B. Finn J.P. Huang D. Bordelon Y. Mintz J. Perlman S. Myelin breakdown and iron changes in Huntington’s disease: Pathogenesis and treatment implications Neurochem. Res. 2007 32 1655 1664 10.1007/s11064-007-9352-7 17484051
94. Phillips O. Squitieri F. Sanchez-Castaneda C. Elifani F. Caltagirone C. Sabatini U. Di Paola M. Deep white matter in Huntington’s disease PLoS ONE 2014 9 e109676 25340651
95. Bardile C.F. Garcia-Miralles M. Caron N.S. Rayan N.A. Langley S.R. Harmston N. Rondelli A.M. Teo R.T.Y. Waltl S. Anderson L.M. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease Proc. Natl. Acad. Sci. USA 2019 116 9622 9627 10.1073/pnas.1818042116 31015293
96. Huang B. Wei W. Wang G. Gaertig M.A. Feng Y. Wang W. Li X.J. Li S. Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes Neuron 2015 85 1212 1226 10.1016/j.neuron.2015.02.026 25789755
97. Wang N. Yang X.W. Huntington disease’s glial progenitor cells hit the pause button in the mouse brain Cell Stem. Cell 2019 24 3 4 10.1016/j.stem.2018.12.004 30609397
98. Cui L. Jeong H. Borovecki F. Parkhurst C.N. Tanese N. Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 2006 127 59 69 10.1016/j.cell.2006.09.015 17018277
99. Johri A. Chandra A. Beal M.F. PGC-1α, mitochondrial dysfunction, and Huntington’s disease Free Radic. Biol. Med. 2013 62 37 46 10.1016/j.freeradbiomed.2013.04.016 23602910
100. Xiang Z. Valenza M. Cui L. Leoni V. Jeong H.K. Brilli E. Zhang J. Peng Q. Duan W. Reeves S.A. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington’s disease J. Neurosci. 2011 31 9544 9553 10.1523/JNEUROSCI.1291-11.2011 21715619
101. Ryu H. Ferrante R.J. Emerging chemotherapeutic strategies for Huntington’s disease Expert Opin. Emerg. Drugs 2005 10 345 363 10.1517/14728214.10.2.345 15934871
102. Allis C.D. Jenuwein T. The molecular hallmarks of epigenetic control Nat. Rev. Genet. 2016 17 487 500 10.1038/nrg.2016.59 27346641
103. Kuehner J.N. Bruggeman E.C. Wen Z. Yao B. Epigenetic regulations in neuropsychiatric disorders Front. Genet. 2019 10 268 10.3389/fgene.2019.00268 31019524
104. Liu C. Jiao C. Wang K. Yuan N. DNA methylation and psychiatric disorders Prog Mol. Biol. Transl. Sci. 2018 157 175 232 29933950
105. Grayson D.R. Guidotti A. The dynamics of DNA methylation in Schizophrenia and related psychiatric disorders Neuropsychopharmacology 2013 38 138 166 10.1038/npp.2012.125 22948975
106. Suzuki M.M. Bird A. DNA methylation landscapes: Provocative insights from epigenomics Nat. Rev. Genet. 2008 9 465 476 10.1038/nrg2341 18463664
107. Ng C.W. Yildirim F. Yap Y.S. Dalin S. Matthews B.J. Velez P.J. Labadorf A. Housman D.E. Fraenkel E. Extensive changes in DNA methylation are associated with expression of mutant huntingtin Proc. Natl. Acad. Sci. USA 2013 110 2354 2359 10.1073/pnas.1221292110 23341638
108. Beal M.F. Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington’s disease Nat. Rev. Neurosci. 2004 5 373 384 10.1038/nrn1386 15100720
109. Lee J. Hwang Y.J. Ryu H. Kowall N.W. Ryu H. Nucleolar dysfunction in Huntington’s disease Biochim. Biophys Acta 2014 1842 785 790 10.1016/j.bbadis.2013.09.017 24184605
110. Korzus E. Rosenfeld M.G. Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation Neuron 2004 42 961 972 10.1016/j.neuron.2004.06.002 15207240
111. Glajch K.E. Sadri-Vakili G. Epigenetic mechanisms involved in Huntington’s disease pathogenesis J. Huntingt. Dis. 2015 4 1 15 10.3233/JHD-140134
112. Jiang H. Poirier M.A. Liang Y. Pei Z. Weiskittel C.E. Smith W.W. DeFranco D.B. Ross C.A. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin Neurobiol. Dis. 2006 23 543 551 10.1016/j.nbd.2006.04.011 16766198
113. McFarland K.N. Das S. Sun T.T. Leyfer D. Xia E. Sangrey G.R. Kuhn A. Luthi-Carter R. Clark T.W. Sadri-Vakili G. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington’s disease PLoS ONE 2012 7 e41423 10.1371/journal.pone.0041423 22848491
114. Sadri-Vakili G. Bouzou B. Benn C.L. Kim M.O. Chawla P. Overland R.P. Glajch K.E. Xia E. Qiu Z. Hersch S.M. Histones associated with downregulated genes are hypo-acetylated in Huntington’s disease models Hum. Mol. Genet. 2007 16 1293 1306 10.1093/hmg/ddm078 17409194
115. Ryu H. Lee J. Hagerty S.W. Soh B.Y. McAlpin S.E. Cormier K.A. Smith K.M. Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington’s disease Proc. Natl. Acad. Sci. USA 2006 103 19176 19181 10.1073/pnas.0606373103 17142323
116. De Pietri Tonelli D. Pulvers J.N. Haffner C. Murchison E.P. Hannon G.J. Huttner W.B. miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex Development 2008 135 3911 3921 10.1242/dev.025080 18997113
117. Dong X. Cong S. MicroRNAs in Huntington’s disease: Diagnostic biomarkers or therapeutic agents? Front. Cell. Neurosci. 2021 15 313 10.3389/fncel.2021.705348
118. Juźwik C.A. Drake S.S. Zhang Y. Paradis-Isler N. Sylvester A. Amar-Zifkin A. Douglas C. Morquette B. Moore C.S. Fournier A.E. microRNA dysregulation in neurodegenerative diseases: A systematic review Prog. Neurobiol. 2019 182 101664 10.1016/j.pneurobio.2019.101664 31356849
119. Sinha M. Ghose J. Bhattarcharyya N.P. Micro RNA -214,-150,-146a and-125b target Huntingtin gene RNA Biol. 2011 8 1005 1021 10.4161/rna.8.6.16035 22048026
120. Das S. Bhattacharyya N.P. Heat shock factor 1-regulated miRNAs can target Huntingtin and suppress aggregates of mutant huntingtin Microrna 2015 4 185 193 10.2174/2211536605666151204111323 26634350
121. Kozlowska E. Krzyzosiak W.J. Koscianska E. Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs Int. J. Mol. Sci. 2013 14 16999 17016 10.3390/ijms140816999 23965969
122. Bucha S. Mukhopadhyay D. Bhattacharyya N.P. Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2 Biochem. Biophys Res. Commun. 2015 465 797 802 10.1016/j.bbrc.2015.08.090 26307536
123. Ma B. Savas J.N. Yu M.-S. Culver B.P. Chao M.V. Tanese N. Huntingtin mediates dendritic transport of β-actin mRNA in rat neurons Sci. Rep. 2011 1 140 10.1038/srep00140 22355657
124. Caviston J.P. Ross J.L. Antony S.M. Tokito M. Holzbaur E.L. Huntingtin facilitates dynein/dynactin-mediated vesicle transport Proc. Natl. Acad. Sci. USA 2007 104 10045 10050 10.1073/pnas.0610628104 17548833
125. Caviston J.P. Holzbaur E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking Trends Cell Biol. 2009 19 147 155 10.1016/j.tcb.2009.01.005 19269181
126. Zala D. Hinckelmann M.-V. Yu H. Da Cunha M.M.L. Liot G. Cordelières F.P. Marco S. Saudou F. Vesicular glycolysis provides on-board energy for fast axonal transport Cell 2013 152 479 491 10.1016/j.cell.2012.12.029 23374344
127. Burke J.R. Enghild J.J. Martin M.E. Jou Y.-S. Myers R.M. Roses A.D. Vance J.M. Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH Nat. Med. 1996 2 347 350 10.1038/nm0396-347 8612237
128. Wu J. Lin F. Qin Z. Sequestration of glyceraldehyde-3-phosphate dehydrogenase to aggregates formed by mutant huntingtin Acta Biochim. Et Biophys. Sin. 2007 39 885 890 10.1111/j.1745-7270.2007.00352.x
129. Chaudhary R.K. Patel K.A. Patel M.K. Joshi R.H. Roy I. Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington’s disease Mol. Ther. 2015 23 1912 1926 10.1038/mt.2015.157 26310631
130. Gauthier L.R. Charrin B.C. Borrell-Pagès M. Dompierre J.P. Rangone H. Cordelières F.P. De Mey J. MacDonald M.E. Leßmann V. Humbert S. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules Cell 2004 118 127 138 10.1016/j.cell.2004.06.018 15242649
131. Twelvetrees A.E. Lesept F. Holzbaur E.L. Kittler J.T. The adaptor proteins HAP1a and GRIP1 collaborate to activate the kinesin-1 isoform KIF5C J. Cell Sci. 2019 132 jcs215822 10.1242/jcs.215822 31757889
132. Colin E. Zala D. Liot G. Rangone H. Borrell-Pagès M. Li X.J. Saudou F. Humbert S. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons EMBO J. 2008 27 2124 2134 10.1038/emboj.2008.133 18615096
133. Warby S.C. Chan E.Y. Metzler M. Gan L. Singaraja R.R. Crocker S.F. Robertson H.A. Hayden M.R. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo Hum. Mol. Genet. 2005 14 1569 1577 10.1093/hmg/ddi165 15843398
134. Guo W. Dittlau K.S. Van Den Bosch L. Axonal transport defects and neurodegeneration: Molecular mechanisms and therapeutic implications Semin. Cell Dev. Biol. 2020 99 133 150 10.1016/j.semcdb.2019.07.010 31542222
135. Morfini G. Pigino G. Brady S.T. Polyglutamine expansion diseases: Failing to deliver Trends Mol. Med. 2005 11 64 70 10.1016/j.molmed.2004.12.002 15694868
136. Her L.-S. Goldstein L.S. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin J. Neurosci. 2008 28 13662 13672 10.1523/JNEUROSCI.4144-08.2008 19074039
137. Li H. Li S.-H. Yu Z.-X. Shelbourne P. Li X.-J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington’s disease mice J. Neurosci. 2001 21 8473 8481 10.1523/JNEUROSCI.21-21-08473.2001 11606636
138. White J.A. Krzystek T.J. Hoffmar-Glennon H. Thant C. Zimmerman K. Iacobucci G. Vail J. Thurston L. Rahman S. Gunawardena S. Excess Rab4 rescues synaptic and behavioral dysfunction caused by defective HTT-Rab4 axonal transport in Huntington’s disease Acta Neuropathol. Commun. 2020 8 97 10.1186/s40478-020-00964-z 32611447
139. Liot G. Zala D. Pla P. Mottet G. Piel M. Saudou F. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites J. Neurosci. 2013 33 6298 6309 10.1523/JNEUROSCI.2033-12.2013 23575829
140. Wong Y.C. Holzbaur E.L. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation J. Neurosci. 2014 34 1293 10.1523/JNEUROSCI.1870-13.2014 24453320
141. Gunawardena S. Her L.-S. Brusch R.G. Laymon R.A. Niesman I.R. Gordesky-Gold B. Sintasath L. Bonini N.M. Goldstein L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila Neuron 2003 40 25 40 10.1016/S0896-6273(03)00594-4 14527431
142. Dompierre J.P. Godin J.D. Charrin B.C. Cordelieres F.P. King S.J. Humbert S. Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation J. Neurosci. 2007 27 3571 3583 10.1523/JNEUROSCI.0037-07.2007 17392473
143. Qin Z.-H. Wang Y. Sapp E. Cuiffo B. Wanker E. Hayden M.R. Kegel K.B. Aronin N. DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction J. Neurosci. 2004 24 269 281 10.1523/JNEUROSCI.1409-03.2004 14715959
144. Liu Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line J. Biol. Chem. 1998 273 28873 28877 10.1074/jbc.273.44.28873 9786889
145. Morfini G.A. You Y.-M. Pollema S.L. Kaminska A. Liu K. Yoshioka K. Björkblom B. Coffey E.T. Bagnato C. Han D. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin Nat. Neurosci. 2009 12 864 871 10.1038/nn.2346 19525941
146. Gelman A. Rawet-Slobodkin M. Elazar Z. Huntingtin facilitates selective autophagy Nat. Cell Biol. 2015 17 214 215 10.1038/ncb3125 25720962
147. Rui Y.N. Xu Z. Patel B. Chen Z. Chen D. Tito A. David G. Sun Y. Stimming E.F. Bellen H.J. Huntingtin functions as a scaffold for selective macroautophagy Nat. Cell Biol. 2015 17 262 275 10.1038/ncb3101 25686248
148. Ochaba J. Lukacsovich T. Csikos G. Zheng S. Margulis J. Salazar L. Mao K. Lau A.L. Yeung S.Y. Humbert S. Potential function for the Huntingtin protein as a scaffold for selective autophagy Proc. Natl. Acad. Sci. USA 2014 111 16889 16894 10.1073/pnas.1420103111 25385587
149. Braatz E.M. André E.A. Liu J.P. Zeitlin S.O. Characterization of a knock-in mouse model with a huntingtin exon 1 deletion J. Huntingt. Dis. 2021 10 435 454 10.3233/JHD-210494 34459410
150. Atwal R.S. Truant R. A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy Autophagy 2008 4 91 93 10.4161/auto.5201 17986868
151. Barron J.C. Hurley E.P. Parsons M.P. Huntingtin and the synapse Front. Cell Neurosci. 2021 15 225 10.3389/fncel.2021.689332
152. McAdam R.L. Morton A. Gordon S.L. Alterman J.F. Khvorova A. Cousin M.A. Smillie K.J. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt(Q140/Q140) mouse model of Huntington’s disease Neurobiol. Dis. 2020 134 104637 10.1016/j.nbd.2019.104637 31614197
153. Bonfanti S. Lionetti M.C. Fumagalli M.R. Chirasani V.R. Tiana G. Dokholyan N.V. Zapperi S. La Porta C.A.M. Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins Sci. Rep. 2019 9 7615 10.1038/s41598-019-44151-0 31110208
154. Bečanović K. Nørremølle A. Neal S.J. Kay C. Collins J.A. Arenillas D. Lilja T. Gaudenzi G. Manoharan S. Doty C.N. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease Nat. Neurosci. 2015 18 807 816 10.1038/nn.4014 25938884
155. O’Regan G.C. Farag S.H. Ostroff G.R. Tabrizi S.J. Andre R. Wild-type huntingtin regulates human macrophage function Sci Rep. 2020 10 17269 10.1038/s41598-020-74042-8 33057179
156. Bensalel J. Xu H. Lu M.L. Capobianco E. Wei J. RNA-seq analysis reveals significant transcriptome changes in huntingtin-null human neuroblastoma cells BMC Med. Genom. 2021 14 176 10.1186/s12920-021-01022-w 34215255
157. Guo Q. Huang B. Cheng J. Seefelder M. Engler T. Pfeifer G. Oeckl P. Otto M. Moser F. Maurer M. The cryo-electron microscopy structure of huntingtin Nature 2018 555 117 120 10.1038/nature25502 29466333
158. Kaemmerer W.F. Grondin R.C. The effects of huntingtin-lowering: What do we know so far? Degener Neurol. Neuromuscul. Dis. 2019 9 3 17 10.2147/DNND.S163808 30881191
159. Burtscher J. Di Pardo A. Maglione V. Schwarzer C. Squitieri F. Mitochondrial respiration changes in R6/2 Huntington’s disease model mice during aging in a brain region specific manner Int. J. Mol. Sci. 2020 21 5412 10.3390/ijms21155412
160. Cherubini M. Lopez-Molina L. Gines S. Mitochondrial fission in Huntington’s disease mouse striatum disrupts ER-mitochondria contacts leading to disturbances in Ca2+ efflux and reactive oxygen species (ROS) homeostasis Neurobiol. Dis. 2020 136 104741 10.1016/j.nbd.2020.104741 31931142
161. Costa V. Giacomello M. Hudec R. Lopreiato R. Ermak G. Lim D. Malorni W. Davies K.J. Carafoli E. Scorrano L. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli EMBO Mol. Med. 2010 2 490 503 10.1002/emmm.201000102 21069748
162. Damiano M. Galvan L. Déglon N. Brouillet E. Mitochondria in Huntington’s disease Biochim. Biophys Acta 2010 1802 52 61 10.1016/j.bbadis.2009.07.012 19682570
163. Jędrak P. Krygier M. Tońska K. Drozd M. Kaliszewska M. Bartnik E. Sołtan W. Sitek E.J. Stanisławska-Sachadyn A. Limon J. Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts Metab. Brain Dis. 2017 32 1237 1247 10.1007/s11011-017-0026-0 28508341
164. Kim J. Moody J.P. Edgerly C.K. Bordiuk O.L. Cormier K. Smith K. Beal M.F. Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease Hum. Mol. Genet. 2010 19 3919 3935 10.1093/hmg/ddq306 20660112
165. Song W. Chen J. Petrilli A. Liot G. Klinglmayr E. Zhou Y. Poquiz P. Tjong J. Pouladi M.A. Hayden M.R. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity Nat. Med. 2011 17 377 382 10.1038/nm.2313 21336284
166. Jodeiri Farshbaf M. Ghaedi K. Huntington’s disease and mitochondria Neurotox. Res. 2017 32 518 529 10.1007/s12640-017-9766-1 28639241
167. Wang J.-Q. Chen Q. Wang X. Wang Q.-C. Wang Y. Cheng H.-P. Guo C. Sun Q. Chen Q. Tang T.-S. Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease J. Biol. Chem. 2013 288 3070 3084 10.1074/jbc.M112.407726 23250749
168. Elena-Real C.A. Díaz-Quintana A. González-Arzola K. Velázquez-Campoy A. Orzáez M. López-Rivas A. Gil-Caballero S. De la Rosa M.Á. Díaz-Moreno I. Cytochrome c speeds up caspase cascade activation by blocking 14-3-3ε-dependent Apaf-1 inhibition Cell Death Dis. 2018 9 365 10.1038/s41419-018-0408-1 29511177
169. Ryu H. Rosas H.D. Hersch S.M. Ferrante R.J. The therapeutic role of creatine in Huntington’s disease Pharm 2005 108 193 207 10.1016/j.pharmthera.2005.04.008
170. Palmer C.S. Anderson A.J. Stojanovski D. Mitochondrial protein import dysfunction: Mitochondrial disease, neurodegenerative disease and cancer FEBS Lett. 2021 595 1107 1131 10.1002/1873-3468.14022 33314127
171. Franco-Iborra S. Plaza-Zabala A. Montpeyo M. Sebastian D. Vila M. Martinez-Vicente M. Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease Autophagy 2021 17 672 689 10.1080/15548627.2020.1728096 32093570
172. Ismailoglu I. Chen Q. Popowski M. Yang L. Gross S.S. Brivanlou A.H. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells Dev. Biol. 2014 391 230 240 10.1016/j.ydbio.2014.04.005 24780625
173. Kim A. Lalonde K. Truesdell A. Gomes Welter P. Brocardo P.S. Rosenstock T.R. Gil-Mohapel J. New avenues for the treatment of Huntington’s disease Int. J. Mol. Sci. 2021 22 8363 10.3390/ijms22168363 34445070
174. Shin J.W. Kim K.-H. Chao M.J. Atwal R.S. Gillis T. MacDonald M.E. Gusella J.F. Lee J.-M. Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9 Hum. Mol. Genet. 2016 25 4566 4576 10.1093/hmg/ddw286 28172889
175. Monteys A.M. Ebanks S.A. Keiser M.S. Davidson B.L. CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo Mol. Ther. 2017 25 12 23 10.1016/j.ymthe.2016.11.010 28129107
176. Yang S. Chang R. Yang H. Zhao T. Hong Y. Kong H.E. Sun X. Qin Z. Jin P. Li S. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease J. Clin. Investig. 2017 127 2719 2724 10.1172/JCI92087 28628038
177. Ekman F.K. Ojala D.S. Adil M.M. Lopez P.A. Schaffer D.V. Gaj T. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington’s disease mouse model Mol. Ther.-Nucleic Acids 2019 17 829 839 10.1016/j.omtn.2019.07.009 31465962
178. Agustín-Pavón C. Mielcarek M. Garriga-Canut M. Isalan M. Deimmunization for gene therapy: Host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice Mol. Neurodegener 2016 11 64 10.1186/s13024-016-0128-x 27600816
179. Garriga-Canut M. Agustín-Pavón C. Herrmann F. Sánchez A. Dierssen M. Fillat C. Isalan M. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice Proc. Natl. Acad. Sci. USA 2012 109 E3136 E3145 10.1073/pnas.1206506109 23054839
180. Huang B. Schiefer J. Sass C. Landwehrmeyer G.B. Kosinski C.M. Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo Hum. Gene Ther. 2007 18 303 311 10.1089/hum.2006.160 17472569
181. Harper S.Q. Staber P.D. He X. Eliason S.L. Martins I.H. Mao Q. Yang L. Kotin R.M. Paulson H.L. Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model Proc. Natl. Acad. Sci. USA 2005 102 5820 5825 10.1073/pnas.0501507102 15811941
182. Drouet V. Perrin V. Hassig R. Dufour N. Auregan G. Alves S. Bonvento G. Brouillet E. Luthi-Carter R. Hantraye P. Sustained effects of nonallele-specific Huntingtin silencing Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc. 2009 65 276 285
183. DiFiglia M. Sena-Esteves M. Chase K. Sapp E. Pfister E. Sass M. Yoder J. Reeves P. Pandey R.K. Rajeev K.G. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc. Natl. Acad. Sci. USA 2007 104 17204 17209 10.1073/pnas.0708285104 17940007
184. Yu D. Pendergraff H. Liu J. Kordasiewicz H.B. Cleveland D.W. Swayze E.E. Lima W.F. Crooke S.T. Prakash T.P. Corey D.R. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression Cell 2012 150 895 908 10.1016/j.cell.2012.08.002 22939619
185. McBride J.L. Boudreau R.L. Harper S.Q. Staber P.D. Monteys A.M. Martins I. Gilmore B.L. Burstein H. Peluso R.W. Polisky B. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi Proc. Natl. Acad. Sci. USA 2008 105 5868 5873 10.1073/pnas.0801775105 18398004
186. Aguiar S. van der Gaag B. Cortese F.A.B. RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA Transl. Neurodegener. 2017 6 30 10.1186/s40035-017-0101-9 29209494
187. Keskin S. Brouwers C.C. Sogorb-Gonzalez M. Martier R. Depla J.A. Vallès A. van Deventer S.J. Konstantinova P. Evers M.M. AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes Mol. Ther.-Methods Clin. Dev. 2019 15 275 284 10.1016/j.omtm.2019.09.010 31737741
188. Matthes F. Massari S. Bochicchio A. Schorpp K. Schilling J. Weber S. Offermann N. Desantis J. Wanker E. Carloni P. Reducing mutant huntingtin protein expression in living cells by a newly identified RNA CAG binder ACS Chem. Neurosci. 2018 9 1399 1408 10.1021/acschemneuro.8b00027 29506378
189. Lopes C. Tang Y. Anjo S.I. Manadas B. Onofre I. De Almeida L.P. Daley G.Q. Schlaeger T.M. Rego A.C.C. Mitochondrial and redox modifications in huntington disease induced pluripotent stem cells rescued by CRISPR/Cas9 CAGs targeting Front. Cell Dev. Biol. 2020 8 967 10.3389/fcell.2020.576592
190. Dos Santos N.T.H. do Bomfim F.R.C. Gene editing by CRISPR/CAS9 for treatment of Huntington disease Int. J. Dev. Res. 2020 10 38631 38635
191. Jamwal S. Elsworth J.D. Rahi V. Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: Emphasis on recent updates and future perspectives Expert Rev. Neurother. 2020 20 1123 1141 10.1080/14737175.2020.1801424 32720531
192. Marxreiter F. Stemick J. Kohl Z. Huntingtin lowering strategies Int. J. Mol. Sci. 2020 21 2146 10.3390/ijms21062146 32245050
193. Leavitt B.R. Kordasiewicz H.B. Schobel S.A. Huntingtin-lowering therapies for Huntington disease: A review of the evidence of potential benefits and risks JAMA Neurol. 2020 77 764 772 10.1001/jamaneurol.2020.0299 32202594
194. Tabrizi S.J. Flower M.D. Ross C.A. Wild E.J. Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities Nat. Rev. Neurol. 2020 16 529 546 10.1038/s41582-020-0389-4 32796930
195. Tabrizi S.J. Ghosh R. Leavitt B.R. Huntingtin lowering strategies for disease modification in Huntington’s disease Neuron 2019 101 801 819 10.1016/j.neuron.2019.01.039 30844400
196. Estevez-Fraga C. Flower M.D. Tabrizi S.J. Therapeutic strategies for Huntington’s disease Curr. Opin. Neurol. 2020 33 508 518 10.1097/WCO.0000000000000835 32657893
197. Evers M.M. Konstantinova P. AAV5-miHTT gene therapy for Huntington disease: Lowering both huntingtins Expert Opin. Biol. Ther. 2020 20 1121 1124 10.1080/14712598.2020.1792880 32658606
198. Barker R. Fujimaki M. Rogers P. Rubinsztein D. Huntingtin-lowering strategies for Huntington’s disease Expert Opin. Investig. Drugs 2020 29 1125 1132 10.1080/13543784.2020.1804552 32745442
199. Smith A.V. Tabrizi S.J. Therapeutic antisense targeting of huntingtin DNA Cell Biol. 2020 39 154 158 10.1089/dna.2019.5188 31821021
200. Fields E. Vaughan E. Tripu D. Lim I. Shrout K. Conway J. Salib N. Lee Y. Dhamsania A. Jacobsen M. Gene targeting techniques for Huntington’s disease Ageing Res. Rev. 2021 70 101385 10.1016/j.arr.2021.101385 34098113
201. Wild E.J. Tabrizi S.J. Therapies targeting DNA and RNA in Huntington’s disease Lancet Neurol. 2017 16 837 847 10.1016/S1474-4422(17)30280-6 28920889
202. Gardian G. Browne S.E. Choi D.-K. Klivenyi P. Gregorio J. Kubilus J.K. Ryu H. Langley B. Ratan R.R. Ferrante R.J. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease J. Biol. Chem. 2005 280 556 563 10.1074/jbc.M410210200 15494404
203. Ferrante R.J. Kubilus J.K. Lee J. Ryu H. Beesen A. Zucker B. Smith K. Kowall N.W. Ratan R.R. Luthi-Carter R. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice J. Neurosci. 2003 23 9418 9427 10.1523/JNEUROSCI.23-28-09418.2003 14561870
204. Thomas E.A. Coppola G. Desplats P.A. Tang B. Soragni E. Burnett R. Gao F. Fitzgerald K.M. Borok J.F. Herman D. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice Proc. Natl. Acad. Sci. USA 2008 105 15564 15569 10.1073/pnas.0804249105 18829438
205. Jia H. Morris C.D. Williams R.M. Loring J.F. Thomas E.A. HDAC inhibition imparts beneficial transgenerational effects in Huntington’s disease mice via altered DNA and histone methylation Proc. Natl. Acad. Sci. USA 2015 112 E56 E64 10.1073/pnas.1415195112 25535382
206. Jia H. Pallos J. Jacques V. Lau A. Tang B. Cooper A. Syed A. Purcell J. Chen Y. Sharma S. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington’s disease Neurobiol. Dis. 2012 46 351 361 10.1016/j.nbd.2012.01.016 22590724
207. Siebzehnrübl F.A. Raber K.A. Urbach Y.K. Schulze-Krebs A. Canneva F. Moceri S. Habermeyer J. Achoui D. Gupta B. Steindler D.A. Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition Proc. Natl. Acad. Sci. USA 2018 115 E8765 E8774 10.1073/pnas.1807962115 30150378
208. Guedes-Dias P. de Proença J. Soares T.R. Leitão-Rocha A. Pinho B.R. Duchen M.R. Oliveira J.M. HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis. 2015 1852 2484 2493 10.1016/j.bbadis.2015.08.012 26300485
209. Ferrante R.J. Ryu H. Kubilus J.K. D’Mello S. Sugars K.L. Lee J. Lu P. Smith K. Browne S. Beal M.F. Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington’s disease J. Neurosci. 2004 24 10335 10342 10.1523/JNEUROSCI.2599-04.2004 15548647
210. Heiser V. Scherzinger E. Boeddrich A. Nordhoff E. Lurz R. Schugardt N. Lehrach H. Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington’s disease therapy Proc. Natl. Acad. Sci. USA 2000 97 6739 6744 10.1073/pnas.110138997 10829068
211. Tanaka M. Machida Y. Niu S. Ikeda T. Jana N.R. Doi H. Kurosawa M. Nekooki M. Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease Nat. Med. 2004 10 148 154 10.1038/nm985 14730359
212. Lee C.Y.D. Wang N. Shen K. Stricos M. Langfelder P. Cheon K.H. Cortés E.P. Vinters H.V. Vonsattel J.P. Wexler N.S. Disease-related Huntingtin seeding activities in cerebrospinal fluids of Huntington’s disease patients Sci. Rep. 2020 10 20295 10.1038/s41598-020-77164-1 33219289
213. Xu X. Ng B. Sim B. Radulescu C.I. Yusof N.A.B.M. Goh W.I. Lin S. Lim J.S.Y. Cha Y. Kusko R. pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model Cell Death Dis. 2020 11 809 10.1038/s41419-020-02983-z 32978366
214. Kratter I.H. Zahed H. Lau A. Tsvetkov A.S. Daub A.C. Weiberth K.F. Gu X. Saudou F. Humbert S. Yang X.W. Serine 421 regulates mutant huntingtin toxicity and clearance in mice J. Clin. Investig. 2016 126 3585 3597 10.1172/JCI80339 27525439
215. Weber J.J. Kloock S.J. Nagel M. Ortiz-Rios M.M. Hofmann J. Riess O. Nguyen H.P. Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease Neuropharmacology 2018 133 94 106 10.1016/j.neuropharm.2018.01.022 29355642
216. Kim M. Lee H. LaForet G. McIntyre C. Martin E.J. Chang P. Kim T.W. Williams M. Reddy P. Tagle D. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition J. Neurosci. 1999 19 964 973 10.1523/JNEUROSCI.19-03-00964.1999 9920660
217. Rieux M. Alpaugh M. Sciacca G. Saint-Pierre M. Masnata M. Denis H.L. Lévesque S.A. Herrmann F. Bazenet C. Garneau A.P. Shedding a new light on Huntington’s disease: How blood can both propagate and ameliorate disease pathology Mol. Psychiatry 2020 26 5441 5463 10.1038/s41380-020-0787-4 32514103
218. Ferrante R.J. Andreassen O.A. Jenkins B.G. Dedeoglu A. Kuemmerle S. Kubilus J.K. Kaddurah-Daouk R. Hersch S.M. Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease J. Neurosci. 2000 20 4389 4397 10.1523/JNEUROSCI.20-12-04389.2000 10844007
219. Koroshetz W.J. Jenkins B.G. Rosen B.R. Beal M.F. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10 Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc. 1997 41 160 165 10.1002/ana.410410206
220. Investigators H.S.G.P.C. Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects Mov. Disord. 2010 25 1924 1928 20669312
221. Essa M.M. Moghadas M. Ba-Omar T. Qoronfleh M.W. Guillemin G.J. Manivasagam T. Justin-Thenmozhi A. Ray B. Bhat A. Chidambaram S.B. Protective effects of antioxidants in Huntington’s disease: An extensive review Neurotox. Res. 2019 35 739 774 10.1007/s12640-018-9989-9 30632085
222. McMeekin L.J. Fox S.N. Boas S.M. Cowell R.M. Dysregulation of PGC-1α-dependent transcriptional programs in neurological and developmental disorders: Therapeutic challenges and opportunities Cells 2021 10 352 10.3390/cells10020352 33572179
223. Lopes C. Ribeiro M. Duarte A.I. Humbert S. Saudou F. De Almeida L.P. Hayden M. Rego A.C. IGF-1 intranasal administration rescues Huntington’s disease phenotypes in YAC128 mice Mol. Neurobiol. 2014 49 1126 1142 10.1007/s12035-013-8585-5 24347322
224. Martin D.D. Ladha S. Ehrnhoefer D.E. Hayden M.R. Autophagy in Huntington disease and huntingtin in autophagy Trends Neurosci. 2015 38 26 35 10.1016/j.tins.2014.09.003 25282404
225. Lo C.H. Pandey N.K. Lim C.K.-W. Ding Z. Tao M. Thomas D.D. Langen R. Sachs J.N. Discovery of small molecule inhibitors of huntingtin exon 1 aggregation by FRET-Based high-throughput screening in living cells ACS Chem. Neurosci. 2020 11 2286 2295 10.1021/acschemneuro.0c00226 32568514
226. Gies E. Wilde I. Winget J.M. Brack M. Rotblat B. Novoa C.A. Balgi A.D. Sorensen P.H. Roberge M. Mayor T. Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition PLoS ONE 2010 5 e14410 10.1371/journal.pone.0014410 21203451
227. Tang T.-S. Slow E. Lupu V. Stavrovskaya I.G. Sugimori M. Llinás R. Kristal B.S. Hayden M.R. Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease Proc. Natl. Acad. Sci. USA 2005 102 2602 2607 10.1073/pnas.0409402102 15695335
228. Farina F. Lambert E. Commeau L. Lejeune F.-X. Roudier N. Fonte C. Parker J.A. Boddaert J. Verny M. Baulieu E.-E. The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington’s disease Sci. Rep. 2017 7 4014 10.1038/s41598-017-04256-w 28638078
229. Ehrnhoefer D.E. Skotte N.H. Reinshagen J. Qiu X. Windshügel B. Jaishankar P. Ladha S. Petina O. Khankischpur M. Nguyen Y.T.N. Activation of caspase-6 is promoted by a mutant huntingtin fragment and blocked by an allosteric inhibitor compound Cell Chem. Biol. 2019 26 1295 1305.e1296 10.1016/j.chembiol.2019.07.001 31353319
230. Wei H. Qin Z.-H. Senatorov V. Wei W. Wang Y. Qian Y. Chuang D.-M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington’s disease Neuroscience 2001 106 603 612 10.1016/S0306-4522(01)00311-6 11591460
231. Ellrichmann G. Blusch A. Fatoba O. Brunner J. Reick C. Hayardeny L. Hayden M. Sehr D. Winklhofer K.F. Saft C. Laquinimod treatment in the R6/2 mouse model Sci. Rep. 2017 7 4947 10.1038/s41598-017-04990-1 28694434
232. Megahed M. El-Azab M.F. El Sayed M.I. Moustafa Y. Huntington’s disease and NMDA receptors; a new arena for therapeutic development Rec. Pharm. Biomed. Sci. 2018 2 1 13 10.21608/rpbs.2018.4037.1005
233. Zhu S. Zhang Y. Bai G. Li H. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington’s disease Cell Death Dis. 2011 2 e115 10.1038/cddis.2010.94 21359116
234. Beconi M.G. Howland D. Park L. Lyons K. Giuliano J. Dominguez C. Munoz-Sanjuan I. Pacifici R. Pharmacokinetics of memantine in rats and mice PLoS Curr. 2011 3 RRN1291 10.1371/currents.RRN1291 22307216
235. Reilmann R. Ross C. Testa C. Frank S. Evers M. de Haan M. Valles-Sanchez A. Konstantinova P. van Deventer S. Higgins J. Translation of AMT-130 preclinical data to inform the design of the first FDA-approved human AAV gene therapy clinical trial in adults with early manifest Huntington’s disease (4531) Neurology 2020 94 4531
236. Tabrizi S.J. Leavitt B.R. Landwehrmeyer G.B. Wild E.J. Saft C. Barker R.A. Blair N.F. Craufurd D. Priller J. Rickards H. Targeting huntingtin expression in patients with Huntington’s disease New Engl. J. Med. 2019 380 2307 2316 10.1056/NEJMoa1900907 31059641
237. Kordasiewicz H.B. Stanek L.M. Wancewicz E.V. Mazur C. McAlonis M.M. Pytel K.A. Artates J.W. Weiss A. Cheng S.H. Shihabuddin L.S. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis Neuron 2012 74 1031 1044 10.1016/j.neuron.2012.05.009 22726834
238. Karpuj M.V. Becher M.W. Springer J.E. Chabas D. Youssef S. Pedotti R. Mitchell D. Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 2002 8 143 149 10.1038/nm0202-143 11821898
239. Dedeoglu A. Kubilus J.K. Jeitner T.M. Matson S.A. Bogdanov M. Kowall N.W. Matson W.R. Cooper A.J. Ratan R.R. Beal M.F. Therapeutic effects of cystamine in a murine model of Huntington’s disease J. Neurosci. 2002 22 8942 8950 10.1523/JNEUROSCI.22-20-08942.2002 12388601
240. Sanchez I. Mahlke C. Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 2003 421 373 379 10.1038/nature01301 12540902
241. Chen M. Ona V.O. Li M. Ferrante R.J. Fink K.B. Zhu S. Bian J. Guo L. Farrell L.A. Hersch S.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat. Med. 2000 6 797 801 10.1038/77528 10888929
242. Rea S. Della-Morte D. Pacifici F. Capuani B. Pastore D. Coppola A. Arriga R. Andreadi A. Donadel G. Di Daniele N. Insulin and exendin-4 reduced mutated Huntingtin accumulation in neuronal cells Front. Pharmacol. 2020 11 779 10.3389/fphar.2020.00779 32547392
243. Di Pardo A. Maglione V. Alpaugh M. Horkey M. Atwal R.S. Sassone J. Ciammola A. Steffan J.S. Fouad K. Truant R. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice Proc. Natl. Acad. Sci. USA 2012 109 3528 3533 10.1073/pnas.1114502109 22331905
244. Ermak G. Hench K.J. Chang K.T. Sachdev S. Davies K.J. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro J. Biol. Chem. 2009 284 11845 11853 10.1074/jbc.M900639200 19270310
245. Rangone H. Poizat G. Troncoso J. Ross C.A. MacDonald M.E. Saudou F. Humbert S. The serum-and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin Eur. J. Neurosci. 2004 19 273 279 10.1111/j.0953-816X.2003.03131.x 14725621
246. Dickey A.S. Pineda V.V. Tsunemi T. Liu P.P. Miranda H.C. Gilmore-Hall S.K. Lomas N. Sampat K.R. Buttgereit A. Torres M.-J.M. PPAR-δ is repressed in Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically Nat. Med. 2016 22 37 45 10.1038/nm.4003 26642438
247. Kim S.J. Li J. Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia Cell Death Dis. 2013 4 e716 10.1038/cddis.2013.238 23846218
248. Morigaki R. Goto S. Striatal vulnerability in Huntington’s disease: Neuroprotection versus neurotoxicity Brain Sci. 2017 7 63 10.3390/brainsci7060063 28590448
249. Casella C. Lipp I. Rosser A. Jones D.K. Metzler-Baddeley C. A critical review of white matter changes in huntington’s disease Mov. Disord. 2020 35 1302 1311 10.1002/mds.28109 32537844
250. Franklin G.L. Camargo C.H.F. Meira A.T. Lima N.S. Teive H.A. The role of the cerebellum in Huntington’s disease: A systematic review Cerebellum 2021 20 254 265 10.1007/s12311-020-01198-4 33029762
251. Reiner A. Deng Y.P. Disrupted striatal neuron inputs and outputs in Huntington’s disease CNS Neurosci. Ther. 2018 24 250 280 10.1111/cns.12844 29582587
252. Yang H.-M. Yang S. Huang S.-S. Tang B.-S. Guo J.-F. Microglial Activation in the Pathogenesis of Huntington’s Disease Front. Aging Neurosci. 2017 9 193 10.3389/fnagi.2017.00193 28674491
253. Cepeda C. Levine M.S. Synaptic dysfunction in Huntington’s disease: Lessons from genetic animal models Neuroscience 2020 1 21 10.1177/1073858420972662 33198566
254. Tang B.L. Unconventional secretion and intercellular transfer of mutant huntingtin Cells 2018 7 59 10.3390/cells7060059
255. Wanker E.E. Ast A. Schindler F. Trepte P. Schnoegl S. The pathobiology of perturbed mutant huntingtin protein–protein interactions in Huntington’s disease J. Neurochem. 2019 151 507 519 10.1111/jnc.14853 31418858
256. Pandey M. Rajamma U. Huntington’s disease: The coming of age J. Genet. 2018 97 649 664 10.1007/s12041-018-0957-1 30027901
257. Tellone E. Galtieri A. Ficarra S. Reviewing biochemical implications of normal and mutated Huntingtin in Huntington’s disease Curr. Med. Chem. 2020 27 5137 5158 10.2174/0929867326666190621101909 31223078
258. Ehrnhoefer D.E. Sutton L. Hayden M.R. Small changes, big impact: Posttranslational modifications and function of huntingtin in Huntington disease Neurosci. 2011 17 475 492 10.1177/1073858410390378
259. Soares T.R. Reis S.D. Pinho B.R. Duchen M.R. Oliveira J.M.A. Targeting the proteostasis network in Huntington’s disease Ageing Res. Rev. 2019 49 92 103 10.1016/j.arr.2018.11.006 30502498
260. Rui Y.-N. Xu Z. Patel B. Cuervo A.M. Zhang S. HTT/Huntingtin in selective autophagy and Huntington disease: A foe or a friend within? Autophagy 2015 11 858 860 10.1080/15548627.2015.1039219 25985010
261. Valionyte E. Yang Y. Roberts S.L. Kelly J. Lu B. Luo S. Lowering mutant huntingtin levels and toxicity: Autophagy-endolysosome pathways in Huntington’s disease J. Mol. Biol. 2020 432 2673 2691 10.1016/j.jmb.2019.11.012 31786267
262. Paul B.D. Snyder S.H. Impaired redox signaling in Huntington’s disease: Therapeutic implications Front. Mol. Neurosci. 2019 12 68 10.3389/fnmol.2019.00068 30941013
263. Dubinsky J.M. Towards an understanding of energy impairment in Huntington’s disease brain J. Huntingt. Dis. 2017 6 267 302 10.3233/JHD-170264 29125492
264. Singh A. Agrawal N. Metabolism in Huntington’s disease: A major contributor to pathology Metab. Brain Dis. 2021 1 15 10.1007/s11011-021-00844-y 32990929
265. Romo L. Mohn E.S. Aronin N. A fresh look at Huntingtin mRNA processing in Huntington’s disease J. Huntingt. Dis. 2018 7 101 108 10.3233/JHD-180292
266. Heinz A. Nabariya D.K. Krauss S. Huntingtin and its role in mechanisms of RNA-mediated toxicity Toxins 2021 13 487 10.3390/toxins13070487 34357961
267. Valadão P.A.C. Santos K.B.S. E Vieira T.H.F. E Cordeiro T.M. Teixeira A.L. Guatimosim C. de Miranda A.S. Inflammation in Huntington’s disease: A few new twists on an old tale J. Neuroimmunol. 2020 348 577380 10.1016/j.jneuroim.2020.577380 32896821
268. Mattis V.B. Svendsen C.N. Modeling Huntington’s disease with patient-derived neurons Brain Res. 2017 1656 76 87 10.1016/j.brainres.2015.10.001 26459990
269. Monk R. Connor B. Cell Reprogramming to Model Huntington’s Disease: A Comprehensive Review Cells 2021 10 1565 10.3390/cells10071565 34206228
270. Kandasamy M. Aigner L. Reactive Neuroblastosis in Huntington’s Disease: A Putative Therapeutic Target for Striatal Regeneration in the Adult Brain Front. Cell. Neurosci. 2018 12 37 10.3389/fncel.2018.00037 29593498
271. Connor B. Concise review: The use of stem cells for understanding and treating Huntington’s disease Stem Cells 2018 36 146 160 10.1002/stem.2747 29178352
272. Colpo G.D. Stimming E.F. Teixeira A.L. Stem cells in animal models of Huntington disease: A systematic review Mol. Cell. Neurosci. 2019 95 43 50 10.1016/j.mcn.2019.01.006 30685323
273. Gorantla V.R. Bhat A. Ghosh A.R. Bolla S.R. Bhojaraj S. Mohan S.K. Veeraraghavan V.P. Chidambaram S.B. Essa M.M. Qoronfleh M.W. Stem cells therapy: A ray of hope for Huntington disease Int. J. Nutr. Pharmacol. Neurol. Dis. 2021 11 95
274. Albin R.L. Kordower J.H. A. Failed Future Mov. Disord. 2020 35 1299 1301 10.1002/mds.28130 32780511
275. Rosser A.E. Busse M. Aron Badin R. Canals J.M. Wheelock V. Perrier A.L. Gray W. Thompson L. Goldman S. Cell therapy for Huntington’s disease: Learning from failure Mov. Disord. 2021 36 787 788 10.1002/mds.28503 33749919
276. Csobonyeiova M. Polak S. Danisovic L. Recent overview of the use of iPSCs Huntington’s disease modeling and therapy Int. J. Mol. Sci. 2020 21 2239 10.3390/ijms21062239 32213859
277. Srinageshwar B. Petersen R.B. Dunbar G.L. Rossignol J. Prion-like mechanisms in neurodegenerative disease: Implications for Huntington’s disease therapy Stem Cells Transl. Med. 2020 9 559 566 10.1002/sctm.19-0248 31997581
278. Bachoud-Lévi A.C. Massart R. Rosser A. Cell therapy in Huntington’s disease: Taking stock of past studies to move the field forward Stem Cells 2021 39 144 155 33176057
279. Choi K.-A. Choi Y. Hong S. Stem cell transplantation for Huntington’s diseases Methods 2018 133 104 112 10.1016/j.ymeth.2017.08.017 28867501
280. Wojtecki L. Groiss S.J. Hartmann C.J. Elben S. Omlor S. Schnitzler A. Vesper J. Deep brain stimulation in Huntington’s disease—preliminary evidence on pathophysiology, efficacy and safety Brain Sci. 2016 6 38 10.3390/brainsci6030038
281. Pini L. Jacquemot C. Cagnin A. Meneghello F. Semenza C. Mantini D. Vallesi A. Aberrant brain network connectivity in presymptomatic and manifest Huntington’s disease: A systematic review Hum. Brain Mapp. 2020 41 256 269 10.1002/hbm.24790 31532053
282. Cardoso F. Chapter fifty-Nonmotor symptoms in Huntington disease International Review of Neurobiology Chaudhuri K.R. Titova N. Academic Press Cambridge, MA 2017 Volume 134 1397 1408
283. Patil R.S. Vyas S.G. Quazi W.T. Tembhurnikar H.J. Milmile P.S. Umekar M.J. The gut microbiome in Huntington disease: A review GSC Biol. Pharm. Sci. 2021 15 317 326 10.30574/gscbps.2021.15.3.0180
284. Schultz J.L. Nopoulos P.C. Gonzalez-Alegre P. Human Immunodeficiency Virus Infection in Huntington’s Disease is Associated with an Earlier Age of Symptom Onset J. Huntingt. Dis. 2018 7 163 166 10.3233/JHD-180287 29843248
285. McCusker E.A. Loy C.T. Huntington disease: The complexities of making and disclosing a clinical diagnosis after premanifest genetic testing Tremor Other Hyperkinet Mov. 2017 7 467 10.5334/tohm.394
286. Przybyl L. Wozna-Wysocka M. Kozlowska E. Fiszer A. What, when and how to measure—peripheral biomarkers in therapy of Huntington’s disease Int. J. Mol. Sci. 2021 22 1561 10.3390/ijms22041561 33557131
287. Schobel S.A. Palermo G. Auinger P. Long J.D. Ma S. Khwaja O.S. Trundell D. Cudkowicz M. Hersch S. Sampaio C. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD Neurology 2017 89 2495 2502 10.1212/WNL.0000000000004743 29142089
288. Claassen D.O. Iyer R.G. Shah-Manek B. DiBonaventura M. Abler V. Sung V.W. Tetrabenazine treatment patterns and outcomes for chorea associated with Huntington disease: A retrospective chart review J. Huntingt. Dis. 2018 7 345 353 10.3233/JHD-170286 30282372
289. Quinn L. Kegelmeyer D. Kloos A. Rao A.K. Busse M. Fritz N.E. Clinical recommendations to guide physical therapy practice for Huntington disease Neurology 2020 94 217 228 10.1212/WNL.0000000000008887 31907286
290. Zarotti N. Dale M. Eccles F. Simpson J. Psychological Interventions for People with Huntington’s Disease: A Call to Arms J. Huntingt. Dis. 2020 9 231 243 10.3233/JHD-200418
291. Eccles F.J.R. Craufurd D. Smith A. Davies R. Glenny K. Homberger M. Peeren S. Rogers D. Rose L. Skitt Z. A feasibility investigation of mindfulness-based cognitive therapy for people with Huntington’s disease Pilot Feasibility Stud. 2020 6 90 10.1186/s40814-020-00631-z 32595978
292. Rossi G. Oh J.C. Management of agitation in Huntington’s disease: A review of the literature Cureus 2020 12 e9748 10.7759/cureus.9748 32944463
293. Liu Q. Cheng S. Yang H. Zhu L. Pan Y. Jing L. Tang B. Li S. Li X.-J. Loss of Hap1 selectively promotes striatal degeneration in Huntington disease mice Proc. Natl. Acad. Sci. USA 2020 117 20265 20273 10.1073/pnas.2002283117 32747555
294. Yang H. Yang S. Jing L. Huang L. Chen L. Zhao X. Yang W. Pan Y. Yin P. Qin Z.S. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form Nat. Commun. 2020 11 2582 10.1038/s41467-020-16318-1 32444599
295. Sharma M. Subramaniam S. Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion J. Cell Biol. 2019 218 1972 1993 10.1083/jcb.201807068 31076452
296. Sharma M. Rajendrarao S. Shahani N. Ramírez-Jarquín U.N. Subramaniam S. Cyclic GMP-AMP synthase promotes the inflammatory and autophagy responses in Huntington disease Proc. Natl. Acad. Sci. USA 2020 117 15989 15999 10.1073/pnas.2002144117 32581130
297. Lee H. Noh J.-Y. Oh Y. Kim Y. Chang J.-W. Chung C.-W. Lee S.-T. Kim M. Ryu H. Jung Y.-K. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux Hum. Mol. Genet. 2011 21 101 114 10.1093/hmg/ddr445 21954231
298. Lee J. Kosaras B. Del Signore S.J. Cormier K. McKee A. Ratan R.R. Kowall N.W. Ryu H. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington’s disease mice Acta Neuropathol. 2011 121 487 498 10.1007/s00401-010-0788-5 21161248
299. Jeon G.S. Kim K.Y. Hwang Y.J. Jung M.-K. An S. Ouchi M. Ouchi T. Kowall N. Lee J. Ryu H. Deregulation of BRCA1 leads to impaired spatiotemporal dynamics of γ-H2AX and DNA damage responses in Huntington’s disease Mol. Neurobiol. 2012 45 550 563 10.1007/s12035-012-8274-9 22580959
300. Hyeon S.J. Park J. Yoo J. Kim S.-H. Hwang Y.J. Kim S.-C. Liu T. Shim H.S. Kim Y. Cho Y. Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington’s disease Prog. Neurobiol. 2021 204 102110 10.1016/j.pneurobio.2021.102110 34166773
301. Mario Isas J. Pandey N.K. Xu H. Teranishi K. Okada A.K. Fultz E.K. Rawat A. Applebaum A. Meier F. Chen J. Huntingtin fibrils with different toxicity, structure, and seeding potential can be interconverted Nat. Commun. 2021 12 4272 10.1038/s41467-021-24411-2 34257293
302. Monteiro O. Chen C. Bingham R. Argyrou A. Buxton R. Jönsson C.P. Jones E. Bridges A. Gatfield K. Krauß S. Pharmacological disruption of the MID1/α4 interaction reduces mutant Huntingtin levels in primary neuronal cultures Neurosci. Lett. 2018 673 44 50 10.1016/j.neulet.2018.02.061 29499308
303. Miyazaki H. Yamanaka T. Oyama F. Kino Y. Kurosawa M. Yamada-Kurosawa M. Yamano R. Shimogori T. Hattori N. Nukina N. FACS-array–based cell purification yields a specific transcriptome of striatal medium spiny neurons in a murine Huntington disease model J. Biol. Chem. 2020 295 9768 9785 10.1074/jbc.RA120.012983 32499373
304. Critchley B.J. Isalan M. Mielcarek M. Neuro-cardio mechanisms in Huntington’s disease and other neurodegenerative disorders Front. Physiol. 2018 9 559 10.3389/fphys.2018.00559 29875678
305. Hsu Y.T. Chang Y.G. Chern Y. Insights into GABA(A)ergic system alteration in Huntington’s disease Open Biol. 2018 8 180165 10.1098/rsob.180165 30518638
306. Burgold J. Schulz-Trieglaff E.K. Voelkl K. Gutiérrez-Ángel S. Bader J.M. Hosp F. Mann M. Arzberger T. Klein R. Liebscher S. Cortical circuit alterations precede motor impairments in Huntington’s disease mice Sci. Rep. 2019 9 6634 10.1038/s41598-019-43024-w 31036840
307. Raj A. Powell F. Network model of pathology spread recapitulates neurodegeneration and selective vulnerability in Huntington’s Disease NeuroImage 2021 235 118008 10.1016/j.neuroimage.2021.118008 33789134
308. Lebouc M. Richard Q. Garret M. Baufreton J. Striatal circuit development and its alterations in Huntington’s disease Neurobiol. Dis. 2020 145 105076 10.1016/j.nbd.2020.105076 32898646
309. Federspiel J.D. Greco T.M. Lum K.K. Cristea I.M. Hdac4 interactions in Huntington’s disease viewed through the prism of multiomics Mol. Cell Proteom. 2019 18 S92 S113 10.1074/mcp.RA118.001253 31040226
310. Cheng J. Liu H.P. Lin W.Y. Tsai F.J. Identification of contributing genes of Huntington’s disease by machine learning BMC Med. Genom. 2020 13 176 10.1186/s12920-020-00822-w
311. Seefelder M. Kochanek S. A meta-analysis of transcriptomic profiles of Huntington’s disease patients PLoS ONE 2021 16 e0253037 34111223
312. Imamura T. Fujita K. Tagawa K. Ikura T. Chen X. Homma H. Tamura T. Mao Y. Taniguchi J.B. Motoki K. Identification of hepta-histidine as a candidate drug for Huntington’s disease by in silico-in vitro- in vivo-integrated screens of chemical libraries Sci. Rep. 2016 6 33861 10.1038/srep33861 27653664
313. Kumar S. Panwar S. Sharma M.K. Sharma M.K. Genes to drug: An in-silico approach to design a drug for Huntington disease (HD) in Homo sapiens Int. J. Comput. Biol. Drug Des. 2021 14 190 201 10.1504/IJCBDD.2021.117184
314. Kohli H. Kumar P. Ambasta R.K. In silico designing of putative peptides for targeting pathological protein Htt in Huntington’s disease Heliyon 2021 7 e06088 10.1016/j.heliyon.2021.e06088 33659724
315. Sundaram J.R. Wu Y. Lee I.C. George S.E. Hota M. Ghosh S. Kesavapany S. Ahmed M. Tan E.-K. Shenolikar S. PromISR-6, a guanabenz analogue, improves cellular survival in an experimental model of Huntington’s disease ACS Chem. Neurosci. 2019 10 3575 3589 10.1021/acschemneuro.9b00185 31313908
316. Deepa S. Rymbai E. Praveen T. Saravanan J. Neuroprotective effects of farnesol on motor and cognitive impairment against 3-nitropropionic acid-induced Huntington’s disease Thai J. Pharm. Sci. 2021 45 16 23

